Generation of recombinant human respiratory syncytial viruses to study antigenic subtype differences, attachment glycoprotein evolution, and polymerase localization by Olinger, Grace Y.
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Generation of recombinant human
respiratory syncytial viruses to
study antigenic subtype
differences, attachment
glycoprotein evolution, and
polymerase localization
https://hdl.handle.net/2144/26475
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
GENERATION OF RECOMBINANT HUMAN RESPIRATORY SYNCYTIAL 
VIRUSES TO STUDY ANTIGENIC SUBTYPE DIFFERENCES, ATTACHMENT 
GLYCOPROTEIN EVOLUTION, AND POLYMERASE LOCALIZATION 
 
 
 
by 
 
 
 
 
 
GRACE YOONHEEKEE OLINGER 
 
B.S., University of Missouri, 2013 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 GRACE Y. OLINGER 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader ___________________________________________________ 
 W. Paul Duprex, Ph.D. 
 Professor of Microbiology 
 
 
Second Reader ___________________________________________________ 
 John H. Connor, Ph.D. 
 Associate Professor of Microbiology 
 
 iv 
 
DEDICATION 
 
 
 
 
I would like to dedicate this work to my late mother, who passed away from her 
battle with cancer. She is the inspiration for my passion in biomedical research. 
 
 
  
 v 
 
ACKNOWLEDGMENTS 
 
I would like to thank my mentor, Dr. W. Paul Duprex for his guidance and support. 
I would also like to thank the current and former laboratory members of Duprex 
laboratory, Dr. Linda Rennick, Dr. Sham Nambulli, Dr. Natasha Tilston-Lunel, 
Gregory Ho, Andrew Acciardo, and Dr. Martin Ludlow, who have been helpful and 
supportive. I would also like to thank the department of Microbiology at Boston 
University School of Medicine, the chair of the department, Dr. Ronald Corley, and 
Director of Graduate Studies, Dr. Gregory Viglianti. I am also grateful for members 
of my former committee, Dr. Rachel Fearns, Dr. Rahm Gummuluru, Dr. Jay 
Mizgerd, and especially for Dr. John Connor, who is also my second thesis reader, 
for their guidance. 
 
I am eternally grateful for my friends and loved ones who have been encouraging 
and supportive in all my endeavors and have been like a family to me; special 
thanks to Leandro Creatini, Raquel Rodriguez, Daniel Taub, Alicia Wooten, Tia 
Mei Potts, and Supapan Thammanok. Finally, I would like to thank my late parents, 
who have instilled in me a passion for knowledge, inspired me to be a better 
person, and taught me that no dream is too big. 
 
  
 vi 
 
GENERATION OF RECOMBINANT HUMAN RESPIRATORY SYNCYTIAL  
 
VIRUSES TO STUDY ANTIGENIC SUBTYPE DIFFERENCES, ATTACHMENT 
 
 GLYCOPROTEIN EVOLUTION, AND POLYMERASE LOCALIZATION 
 
GRACE YOONHEEKEE OLINGER 
ABSTRACT 
  
Human respiratory syncytial virus (HRSV) is a negative sense, single strand 
RNA virus that causes respiratory tract infection with common cold-like symptoms, 
which can be severe in children, immunocompromised, and the elderly. Even with 
60 years of research, the need for vaccine and effective treatment has not been 
met. In this work, recombinant viruses have been generated which will be valuable 
in gaining a better understanding of HRSV subtypes, glycoprotein evolution, and 
the polymerase localization, which would contribute to HRSV vaccine and 
therapeutics development. 
 
The differences in the fitness of A and B antigenic subtypes of HRSV and 
how it affects the regional circulation pattern is not well understood. To study and 
compare the two subtypes, it is important to use clinically relevant recombinant 
viruses and to use animal models that best represent human infection. Using a 
wild-type virus strain (A11 and B05) from each HRSV subtype, a wild-type like 
recombinant (r) virus, rHRSVA11, and recombinant viruses expressing fluorescent 
proteins, rHRSVA11EGFP(5) and rHRSVB05dTom(5), were generated. 
Characterization of rB05 viruses demonstrated that the differences in the 
 vii 
 
fluorescent protein expressed did not affect virus growth kinetics. To prepare for 
an experiment in cotton rats, recombinant HRSVs generated were used to infect 
cotton rat lung cells in vitro. With confirmation of infection of cotton rat lung cells 
by rHRSV, cotton rat co-infection experiment was planned for the recombinant A11 
and B05 viruses and a microneutralization assay was developed for post-infection 
processing of the in vivo samples.  
 
The BA genotype of HRSV B subtype is a strain of HRSV B subtype 
containing a 60 nucleotide duplication in the glycoprotein (G) gene. HRSV BA 
genotype was first isolated in 1998 and has quickly become the predominant 
genotype circulating globally. Although a role of immune evasion by the strains of 
BA genotype has been suggested to explain this phenomenon, few studies have 
supported this hypothesis. To compare the HRSV B subtype virus with and without 
the duplication, rB05 virus lacking the duplication, rHRSVB05EGFP(5)GΔ60b, and 
containing an epitope tag within the duplication, rHRSVB05EGFP(5)Gmycb, were 
generated. A serial passage experiment was set up using rHRSVB05EGFP(5) and 
rHRSVB05EGFP(5)GΔ60b to understand the mutations that accumulate in the G 
protein gene of each virus. This will be valuable in setting up a similar experiment 
in the presence of immune pressure to understand the advantage that is conferred 
to the virus containing the duplication. Expression of Gmyc was confirmed in 
rHRSVB05EGFP(5)Gmyc infection, which validated that this virus can be used to 
study the HRSVB05 G protein and modifications in the duplicated region. 
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 The HRSV large (L) protein is essential in HRSV transcription and 
replication, but is difficult to study due to lack of immunologic reagents and 
challenges with purification. Recombinant viruses expressing reporter and 
polymerase fusion proteins have been generated and used for studying various 
other viral polymerases. Expression plasmids for HRSV L protein containing a 
reporter protein in its variable region 2 have been published. However, the 
modification resulted in downregulation in the function of the protein and rHRSV 
expressing modified L protein have not yet been published. In this study, 
rHRSVB05LVenus was generated to study the effects of modification of HRSV L 
protein variable region and the localization of HRSV L protein. LVenus protein in 
rHRSVB05LVenus infected cells was visualized by confocal laser scanning 
microscopy and the expression levels were examined by immunoblotting. 
rHRSVB05LVenus was compared to rHRSVB05EGFP(5) with unmodified L protein 
to show that modification of HRSV L protein had no effect on virus replication. 
Viruses had equivalent growth kinetics and were equally sensitive to ribavirin, a 
known HRSV inhibitor.  
 
The recombinant viruses generated in this study are valuable tools in 
answering questions that are difficult to pursue without clinically relevant 
recombinant viruses. Characterization of the rHRSVs demonstrated that these 
viruses will have many applications. In this study, viruses were characterized for 
 ix 
 
the basic growth kinetics, expression of proteins of interest, and assay 
development. With these validated tools, questions such as the cause of the 
epidemiological pattern observed for HRSV A and B subtypes, the role of host 
immune response in advantage conferred to HRSV BA genotype, and the effects 
of inhibitors to formation of HRSV polymerase complex can be addressed. 
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CHAPTER 1: INTRODUCTION 
 
1.1 HRSV disease  
 Human respiratory syncytial virus (HRSV) is a nonsegmented, negative (-) 
sense (NNS) single stranded RNA virus in the Pneumoviridae family (Afonso et 
al., 2016; Collins et al., 2013). It infects airway epithelial cells and causes an acute 
respiratory tract infection with symptoms similar to common cold. Infection lasts 
about a week, although prolonged fatal lower respiratory tract infections can occur 
in children, immunocompromised individuals, and the elderly (Byington et al., 
2015; Hall et al., 2013; Ramirez, 2008; Walsh and Falsey, 2012). HRSV is the 
leading cause of bronchiolitis and pneumonia in children under age of five in the 
United States and about 33.8 million children under age of five worldwide were 
infected in 2005 (Hall et al., 2009; Nair et al., 2010). Severe disease is caused by 
high viral load (DeVincenzo et al., 2005; Kim et al., 2015) and by a robust immune 
response to the infection which includes leukocyte infiltration and cytokine 
production (Farrag and Almajhdi, 2015; Johnson and Graham, 1999; Kim et al., 
1969). Reinfections occur throughout life, because HRSV specific antibodies are 
only partially protective, may be subtype or strain specific, and do not last for a 
long time (Habibi et al., 2015; Hall et al., 1991; Openshaw et al., 2017).  
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1.2 HRSV therapeutics  
HRSV was first isolated from a throat swab from an infant in 1957 (Chanock 
et al., 1957). After sixty years of research, there is no vaccine for HRSV (Neuzil, 
2016) and there is still a need for safe and effective treatments (Graham, 2011; 
Simões et al., 2015). There is only one Food and Drug Administration (FDA) 
approved prophylaxis, palivizumab, and one therapeutic treatment, ribavirin, for 
HRSV infection and both are only used for individuals at high risk (Committee on 
Infectious Diseases, 1993; The IMpact RSV Study Group, 1998). Palivizumab is a 
FDA approved humanized monoclonal antibody against the HRSV fusion (F) 
glycoprotein used as an injectable prophylactic in high risk patients, such as 
preterm infants and children with chronic lung disease (American Academy of 
Pediatrics Committee on Infectious Diseases and American Academy of Pediatrics 
Bronchiolitis Guidelines Committee, 2014; Mochizuki et al., 2017; Subramanian et 
al., 1998). Ribavirin is a nucleoside analog used for various viral infections for its 
ability to inhibit virus RNA synthesis, mRNA capping, and depletion of intracellular 
pools of guanosine triphosphate (GTP) (De Clercq and Li, 2016). However, its 
exact mechanism of action in HRSV infected patients is unclear and because of 
the side effects associated with the high therapeutic dosage, it is only used in 
individuals at the highest risk, such as those who are immunocompromised  
(Conrad et al., 1987; Gross and Bryson, 2015; Smith et al., 1991). Development 
of vaccines and treatments has been difficult due to the high mutation rate of HRSV 
which can generate escape mutants (Power, 2008). In addition, the underlying 
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causes leading to HRSV reinfections in the presence of preexisting immunity is 
unclear (Habibi et al., 2015; Power, 2008; Schmidt et al., 2012, 2014; Zhao and 
Sullender, 2005; Zhu et al., 2011).  
 
1.2 HRSV genes and replication 
The HRSV genome is 15.2 kb in length and contains 10 genes which 
encode 11 proteins (Figure 1.1A) (Collins et al., 2013). The leader (Le) noncoding 
sequence at 3’ terminus of the genome contains signals for HRSV genome 
replication, transcription and encapsidation by nucleo-(N) protein (Fearns et al., 
2002; Mink et al., 1991). Trailer (Tr) noncoding sequence at 5’ terminus of HRSV 
genome contains an antigenome promoter for initiation of replication of anti-sense 
viral genome (Fearns et al., 2002; Mink et al., 1991; Peeples and Collins, 2000). 
Each gene is preceded by a gene start (GS) sequence, which is essential for 
transcription initiation, and followed by a gene end (GE) sequence, which is 
essential for transcription termination and mRNA polyadenylation (Collins et al., 
1986; Hardy et al., 1999; Kuo et al., 1997). Noncoding intergenic (Ig) sequences 
between one to 52 nucleotides (nt) long are present at each gene junction between 
the GE and GS sequences (Moudy et al., 2004). Nonstructural (NS) proteins are 
encoded by NS1 and NS2 genes and these interfere with host innate immune 
response (Spann et al., 2005; Swedan et al., 2011; Teng et al., 2000). The N 
protein encapsidates the (-) RNA genome and positive (+) RNA antigenome in a 
helical ribonucleoprotein (RNP). This prevents degradation of the RNA, prevents 
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its detection by host innate immune response, and assists in processive RNA 
replication by the large (L) protein (Fearns and Deval, 2016; Fearns et al., 1997; 
Noton and Fearns, 2011). Together with L protein and a cofactor phospho-(P) 
protein, RNP is the basic unit of infectivity (Fearns and Deval, 2016). P protein is 
a cofactor for HRSV RNA dependent RNA polymerase (RdRp) and mediates 
polymerase complex formation (Castagné et al., 2004; Dupuy et al., 1999). Matrix 
(M) protein is essential in assembly of virions and for maturation of the viral 
filaments (Ghildyal et al., 2006; Henderson et al., 2002; Marty et al., 2004; Mitra et 
al., 2012). Small hydrophobic (SH) protein is a transmembrane protein believed to 
act as a viroporin, forming an ion channel in host cell membranes (Carter et al., 
2010; Gan et al., 2012). Attachment glyco-(G) protein contains  an amino terminal 
cytoplasmic tail domain, transmembrane domain, and carboxy terminal 
ectodomain (Levine et al., 1987; McLellan et al., 2013) (section 1.5). The F 
glycoprotein binds host proteins at the surface of the cell and initiates fusion of 
virion with the plasma membrane (Krzyzaniak et al., 2013; McLellan et al., 2013). 
M2-1 and M2-2 proteins are encoded by the M2 gene and play regulatory roles in 
transcription and replication of the viral genome (Bermingham and Collins, 1999; 
Fearns and Collins, 1999). The L gene with a 68 nt overlap with M2 gene (Hardy 
et al., 1999) encodes the L protein which is the major component of the RdRp and 
is involved in mRNA capping and polyadenylation (Cox and Plemper, 2015; Fearns 
and Deval, 2016) (section 1.3). 
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Binding of virion to the cell plasma membrane and fusion is mediated by the 
G and F glycoproteins (McLellan et al., 2013). After fusion, the (-)RNP is released 
into the cytoplasm (Collins et al., 2013). HRSV genome is transcribed and 
replicated by the RdRp. A start-stop transcription process leads to the generation 
of a transcription gradient of HRSV mRNAs, in which genes at the 3’ end of the 
genome are expressed at a higher level than those at the 5’ end (Barik, 1992). The 
L protein initiates replication of (-)RNA at the 3’ end of the genomoe to generate 
encapsidated (+)RNA, the antigenome. Genome replication at the trailer 
complement sequence of the antigenome and generates (-)RNA genome (Fearns 
et al., 2000). These newly replicated viral antigenome and genome are both 
encapsidated by N protein to form (+) and (-)RNPs. Viral proteins and (-)RNP are 
assembled into virions at the plasma membrane (Figure 1.1B). This process is 
mediated by the M protein (Bajorek et al., 2014; Meshram et al., 2016). Virions bud 
from the host cell at the plasma membrane at the apical surface in ciliated airway 
epithelial cells (Roberts et al., 1995) and in vitro cell-to-cell fusion in nonpolarized 
cells can be mediated by F glycoprotein to cause syncytia (Huong et al., 2016; 
Zhang et al., 2002). 
 
1.3 HRSV L protein 
HRSV L protein is a 250 kDa subunit of RdRp complex. The L and P 
proteins form a basic polymerase complex which is sufficient to initiate RNA
 6 
 
 
 7 
 
synthesis and transcription, but M2-1 is needed for efficient transcription 
elongation (Collins et al., 1996). Due to its large size and difficulties with   
purification of the protein, L protein atomic structure has not been determined. 
Functional domains (Poch et al., 1990; Svenda et al., 1997), such as the 
polymerase domain and the capping domain, of HRSV L protein were identified by 
mutagenesis studies (Fix et al., 2011; Liuzzi et al., 2005).  Six highly conserved 
regions (CR) were identified (Figure 1.2) by comparing primary amino acid 
sequences of L proteins of NNS RNA viruses and these are separated by variable 
linker region (VR) (Poch et al., 1990; Svenda et al., 1997). CR I to III are essential 
for RdRp function and CR IV to VI are essential for the mRNA capping. The VR 
between CR V and CR VI, also known as the hinge region, in other NNS RNA 
viruses, tolerates insertion of epitopes, such as cellular (c)-myc, and fluorescent 
proteins, such as enhanced green fluorescent protein (EGFP) and mCherry. 
Insertion of open reading frames (ORF) of fluorescent proteins into the L gene 
attenuates the wild-type virus and reduce polymerase activity in morbilliviruses and 
rhabdoviruses (Brown et al., 2005; Duprex et al., 2002; Ruedas and Perrault, 
2014). The resulting recombinant (r) viruses have been used for rational 
attenuation of the virus (Silin et al., 2007) and for visualizing the RdRp complex in 
infected cells (Brown et al., 2005; Hoenen et al., 2012; Ruedas and Perrault, 2009).  
 
HRSV L protein has been difficult to study due to its large size, problems 
with purifying the protein, and lack of useful antibodies which bind the protein  
 8 
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unambiguously. One way to overcome these problems has been to generate 
reporter protein tagged L proteins. EGFP and mCherry sequences have been into 
the HRSV L expression plasmids at the sequence encoding VR. The resulting 
protein showed that there was downregulation of RdRp activity of modified L 
protein in minigenome replication transcription assay (Fix et al., 2011). As yet, an 
rHRSV modified L protein containing fluorescent protein has not been reported.  
 
1.4 Antigenic subtypes of HRSV 
 In the 1980s, two antigenic groups of HRSV were described based on the 
binding of a panel of monoclonal antibodies generated from HRSV immunized 
mice to viruses (Anderson et al., 1985; Mufson et al., 1985). These two groups are 
known as antigenic subtypes A and B. Recently, it has become more common to 
determine HRSV subtype using subtype specific primers at the G protein 
ectodomain, since the majority of sequence differences between the subtypes are 
located there  (Coggins et al., 1998; Peret et al., 1998; Sullender et al., 1993; Tan 
et al., 2013). The G proteins of HRSV A and B subtypes have approximately 50% 
amino acid sequence homology (Johnson et al., 1987). Multiple strains of each 
subtype co-circulate in a population, but during any given season, one subtype 
tends to predominate (Peret et al., 1998, 2000). Results from A and B subtype 
sequence and epidemiological differences suggest that lack of cross protection to 
a subtype circulating in previous season contributes to the predominance of  
 10 
 
strains from the other subtype the following year (Schobel et al., 2016; White et 
al., 2005). Much of HRSV research is based on prototypic laboratory adapted 
strains of subtype A (Collins et al., 1995; Moore et al., 2009). HRSV strains of 
subtype A cause higher viral load in patients compared to subtype B (Kim et al., 
2015). This may have an impact on disease severity which is greater in patients 
infected with HRSV subtype A strains (Devincenzo, 2004; DeVincenzo et al., 2005; 
Hall et al., 1990; Jafri et al., 2013; McConnochie et al., 1990; Zhou et al., 2015).  
 
1.5 Intragenic duplication in HRSV G protein gene 
The HRSV G protein is a type II transmembrane glycoprotein comprised of 
289 to 327 amino acids depending on the strain. It has an amino terminal 
cytoplasmic tail (CT) domain followed by a transmembrane (TM) domain (McLellan 
et al., 2013) (Figure 1.3A). The carboxy terminal ectodomain of HRSV G protein 
contains a highly conserved domain (CD) flanked by two highly variable mucin-like 
domains (MLD) (Wertz et al., 1985, 1989). The CD contains a heparin binding 
domain and a disulfide bridge formed by four cysteine residues (Gorman et al., 
1997). Like mucin, the two MLDs are rich in serine, threonine, and proline residues, 
heavily glycosylated, and contain unfolded secondary structures (Wertz et al., 
1985). HRSV G protein is translated in the endoplasmic reticulum (ER) as 32 kDa 
unmodified protein. Glycosylation increases the molecular weight of mature G 
protein to 55 to 100 kDa in transformed cell lines and 180 kDa in primary airway 
epithelial cells (García-Beato et al., 1996; Kwilas et al., 2009). HRSV G protein 
 11 
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exists in both membrane bound and secreted forms, where the secreted protein is 
translated from the second AUG of the mRNA which is located within the TM 
encoding sequence (Hendricks et al., 1987, 1988). HRSV G protein binds heparin 
sulfate proteoglycans (HSPG) (Feldman et al., 1999), CX3C chemokine receptor 
1 (CX3CR1) (Johnson et al., 2015; Stobart et al., 2015), surfactant A (Hickling et 
al., 2000), annexin II (Malhotra et al., 2003), dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) (Johnson et al., 2012), and 
lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN) (Johnson et al., 
2012). Infection of cells that express HSPGs at a high level suggests that G protein 
is not essential for virus entry (Techaarpornkul et al., 2002). However, G protein 
seemed to play an important role in vitro in differentiated human airway epithelial 
cells and in vivo in mice (Teng et al., 2001).  
 
HRSV G protein tolerates major changes in primary sequence. Typically, 
these are caused by changes in G protein gene such as frame-shift mutations 
(García-Barreno et al., 1990), generation of premature stop codons (Martínez et 
al., 1997), and adenosine to guanine hypermutations (Martínez et al., 1997). In 
late 1990’s, isolates of HRSV B subtype containing a 60 nt duplication within the 
G protein gene were isolated (Trento et al., 2003). HRSV genotypes containing 
this duplication were named BA, because they were first isolated in Buenos Aires, 
Argentina. The original BA isolates contained a 60 nt duplication that resulted in 
20 amino acid tandem repeat in MLD2 (Figure 1.3B). The BA genotype has spread 
 13 
globally, replacing preexisting strains of HRSV B subtypes in less than a decade 
(Trento et al., 2010). Although, B subtype strains lacking the duplication have been 
isolated recently, the BA genotype is still the predominant HRSV B strain genotype 
circulating globally (Agoti et al., 2013). A 72 nt duplication, resulting in 36 amino 
acid repeat in MLD2, was found in HRSV A subtypes isolated in Ontario, Canada 
(Eshaghi et al., 2012). The genotype of HRSV A containing this duplication was 
named ON1, and like BA, it is becoming the predominant globally circulating HRSV 
A genotype. Phylogenetic analysis suggest that the duplications in MLD2 have 
been positively selected based on the high frequency of nonsynonymous 
mutations seen in various strains of HRSV (Botosso et al., 2009; Melero et al., 
1997). The nonsynonymous mutations in several amino acid residues in MLD2 can 
revert supporting the hypothesis of role of immune pressure, which changes over 
time in populations, in providing selective pressure to the G protein (Botosso et al., 
2009). However, there has only been one study which sought to elucidate the role 
of 60 nt duplication in HRSV BA genotype. An rHRSV was generated containing 
HRSV A subtype genome with consensus sequence from BA genotype G protein 
genes. There was a slight increase in HRSV BA G protein attachment to host cells 
compared to duplication deletion mutant and no effect on virus neutralization by F 
glycoprotein specific antibody (Hotard et al., 2015).  
 
 14 
1.6 In vivo models of HRSV infection 
 HRSV only infects humans and there is no known animal reservoir (Sacco 
et al., 2015). Mice are the most commonly used animal model for HRSV infection, 
for approximately 77% of published HRSV animal studies (Sa et al., 2010). The 
BALB/c strain is more susceptible than most strains of mice, but infection still 
results in minimal clinical signs of disease and low virus yield compared to the input 
virus (Stark et al., 2002). In mice HRSV infection is restricted to in alveolar 
pneumocytes, in contrast to humans, where ciliated airway epithelial cells are the 
main cell type involved in HRSV infection (Moore et al., 2008). Cotton rats 
(Sigmodon hispidus) are increasingly used as a model in HRSV research, because 
virus replicates in the respiratory tract of cotton rat and the pathology more closely 
resembles human infection (Boukhvalova et al., 2009; Sacco et al., 2015). Similar 
to human infants, cotton rats receive maternal passive immunity to HRSV which 
last up to 18 months (Prince et al., 1983). 
 
1.7 Reverse genetics of HRSV 
 Reverse genetics allows modification of viral genome and examination of 
the changes in phenotype (Bridgen, 2012; Conzelmann, 2004). Approaches to 
generate rHRSV were developed in 1995 and the prototype rHRSVA2, a laboratory-
adapted strain of rHRSV used in HRSV research, was recovered (Collins et al., 
1995). Full-length antigenomic (+)RNA was transcribed from a plasmid containing 
HRSV cDNA downstream of a T7 RNA polymerase promoter and containing T7 
 15 
RNA polymerase terminator at its 3’ end. Sequences of hammerhead ribozyme 
were inserted downstream of HRSV Tr cDNA sequence to cleave the 5’ of the 
antigenome when transcribed. This antigenomic plasmid and plasmids for N, P, 
M2-1, and L protein expression were transfected into cells expressing T7 RNA 
polymerase due to infection by modified vaccinia virus, MVA-T7. After 3 days, 
cytopathic effect (CPE) in transfected cells became visible and the recombinant 
virus were isolated (Bukreyev et al., 1996; Collins et al., 1995).  
 
 Recently modifications to the original protocol includes addition of 
hammerhead ribozyme sequence between the T7 promoter and HRSV Le cDNA 
sequence in the antigenomic plasmid and Hepatitis delta ribozyme sequence 
between the HRSV Tr cDNA sequence and the T7 terminator to generate authentic 
3’ and 5’ of the (-)RNA genome (Been and Wickham, 1997; Bridgen, 2012; Hotard 
et al., 2012).  A range of rHRSV have been generated to study clinically isolated 
strains of HRSV (Lemon et al., 2015), modifications in HRSV proteins (Corry et al., 
2015; Hotard et al., 2015; Schmidt et al., 2014), and attenuated HRSV for possible 
vaccine candidates (Le Nouën et al., 2017; Rostad et al., 2016; Stobart et al., 
2015). To visualize infected cells, fluorescent protein expressing reporter viruses 
have been generated by inserting an additional transcription unit (ATU) containing 
fluorescent protein gene into the viral genome (Figure 1.4) (Duprex et al., 1999; 
Lemon et al., 2015; Ludlow et al., 2012; Schmidt et al., 2011; Whitlow et al., 2006). 
These ATUs  contain the coding region of the fluorescent protein gene with GS 
 16 
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and GE signals of viral genes (Hotard et al., 2012; Lemon et al., 2015; Schnell et 
al., 1996). A recombinant subgroup B HRSV, HRSVB05EGFP(5), which closely 
resembles wild-type, was described which contains EGFP ATU at the position 5 of 
HRSV genome  (Figure 1.4) (Lemon et al., 2015). With unmodified sequence as 
compared to the clinical isolate and low passage number, this virus would better 
represent clinical isolates than laboratory-adapted rHRSV (Kumaria et al., 2011; 
Villenave et al., 2011). 
 
1.8 Aims and objectives 
 The goal of chapter 3 was to examine the differences between HRSV of 
each subtype and to prepare for a coinfection model. Therefore, rHRSV of A and 
B subtypes expressing two different fluorescent proteins were generated and 
characterized. In preparation for in vivo coinfection study in cotton rats, rHRSV 
were tested for infectivity in cotton rat cells and protocols were developed for 
testing the presence of neutralizing antibodies.  
 
 The goal of chapter 4 was to determine the role of the 60 nt duplication in 
G protein gene of HRSV BA genotype. Therefore, rHRSVB05 containing 
modifications in the MLD2 region were generated. These viruses were 
characterized for expression of the modified G protein and G protein gene stability 
over passages. We hypothesize that immune pressure confers replicative 
 18 
advantage to the rHRSV BA genotype. The rHRSV characterization will lead to 
experiments that are more complex to test our hypothesis. 
 
 The goal of chapter 5 was to visualize HRSV L protein in infected cells for 
studying trafficking of L protein and its response to inhibitors. Therefore, rHRSVB05 
containing Venus fluorescent protein gene in the VR of HRSV L protein was 
generated. The expression of modified L protein was characterized. When 
compared, L protein modified virus resembled rHRSVB05EGFP(5), which does not 
contain modified L protein, for growth kinetics and its sensitivity to ribavirin.  
 19 
CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Cells 
2.1.1 Cell lines 
HEp-2 cells (CCL-23), Vero cells (CCL-81), and cotton rat lung cells 
(PTA-3930) were purchased from ATCC.  
 
2.1.2 Cell growth medium 
All tissue culture media, solutions, and fetal bovine serum (FBS) were 
purchased from Thermo Fisher Scientific unless noted otherwise. HEp-2 cells were 
cultured in OptiMEM I Reduced Serum Medium supplemented with 3% (v/v) FBS. 
Vero cells were cultured in AdvancedMEM supplemented with 1% (v/v) GlutaMAX 
and 10% (v/v) FBS. Cotton rat lung cells were cultured in minimal essential 
medium (MEM) with Earle’s Balanced Salt Solution (EBSS) with 2 mM L-glutamine 
(Hyclone) supplemented with 10% (v/v) FBS. Live cell imaging growth medium 
was prepare using Leibovitz medium without phenol red (Gibco) supplemented 
with 20% (v/v) FBS and 100 U/ml of penicillin/streptomycin. Prior to usage, all 
medium was preheated to 37ºC. 
 
2.1.3 Cell biology equipment 
DMIL LED microscope (Leica) was used for routine observing of cells for 
maintenance. For observing cells by phase and UV microscopy, Leica DMI3000B 
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inverted microscope was used. Images were obtained using LAS imaging software 
(Leica). For confocal laser scanning microscopy (CLSM), Leica SP5 II confocal 
microscope was used and images were obtained using LAS AF software (Leica).  
 
For centrifugation of samples containing cells and cell debris, Allegra X-15R 
centrifuge (Beckman Coulter) was used unless noted otherwise. Vari Mix Platform 
Rocker (Thermo Fisher Scientific) was used for all protocols requiring rocking of 
samples for over 1 minute. Cells were maintained in Series 8000 WJ incubator 
(Thermo Fisher Scientific). 
 
2.1.4 Cell maintenance  
Cells were cultured 75cm2 (T75) flasks (Fisher Scientific) for routine 
maintenance. Cells were split when they were 70% to 90% confluent to maintain 
optimal viability. Cells were checked for confluency using an inverted microscope 
(Leica), growth medium was removed, and cells were rinsed with Dulbecco’s 
phosphate buffered saline (DPBS). The cells were treated with 0.25% (w/v) trypsin-
EDTA with phenol red (1ml) and incubated at 37ºC with 5% (v/v) CO2 for up to 10 
minutes to allow cells to detach from the flask. Growth medium (section 2.1.2) was 
added to the flask, cells were suspended by pipetting, and 8% to 50% of the cells 
were added to a new T75 flask. Growth medium was added to the new flask up to 
volume of 15 ml. The cells were incubated at 37ºC in a 5% (v/v) CO2 environment. 
When an exact cell count was needed, cells were counted manually using a 
 21 
hemocytometer (Sigma-Aldrich) and the concentration of cells was determined by 
the following formula: 
 	   =  
   ×,
    !"
 × #	$	  
 
All tissue culture plates were purchased from Fisher Scientific, unless noted 
otherwise. Following volumes of growth medium were used for various tissue 
culture plates: 6-well plates (2 ml), 12-well plates (1.5 ml), 24-well plates (1 ml), 96 
well plates (0.2 ml).  
 
2.2 Viruses 
2.2.1 Virus strains 
HRSVB05 has been previously described (Lemon et al., 2015). HRSVA11 was 
isolated from a clinical sample collected in Belfast, UK during the 2011 HRSV 
season. 
 
2.2.2 Recovery of rHRSV  
One day before transfection, 2 x 106 HEp-2 cells were added to wells in 
6-well plates and incubated at 37ºC, 5% (v/v) CO2 for up to 24 hours. Modified 
vaccinia virus expressing T7 RNA polymerase (MVA-T7) stock (15 µl) in OptiMEM 
(3 ml) was added to each well of cells at an multiplicity of infection (MOI) of 
approximately 0.5 in 6-well plates and incubated at 37ºC, 5% (v/v) CO2 for 25 
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minutes. Infected cells were centrifuged at 1,200 revolutions per minute (rpm), 
30ºC for 20 minutes. Inoculum was removed and each well of cells was transfected 
with pCG-HRSV-N (1.6 µg), pCG-HRSV-P (1.2 µg), pCG-HRSV-M2-1 (0.8 µg), 
pCG-HRSV-L (0.4 µg), and full-length HRSV antigenomic plasmid (1.6 µg) using 
Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s 
specification. OptiMEM was added to the transfected cells which were incubated 
at 37ºC, 5% (v/v) CO2 for at least 18 hours at which point OptiMEM was replaced 
with HEp-2 growth medium. Each day, growth medium was replaced. Cells were 
maintained at 37ºC, 5% (v/v) CO2. When over 80% of the cells were infected as 
determined by CPE or expression of EGFP or Tomato fluorescent tags, cells were 
trypsinized and added to a T75 flask containing 2.5 x 105 HEp-2 cells and 15 ml 
HEp-2 growth medium. Cells were maintained at 37ºC, 5% (v/v) CO2. Each day, 
growth medium was replaced. At the peak of infection, when there was over 80% 
infection and the monolayer disruption was observed, cells and supernatant were 
frozen at -80ºC. Samples were thawed at room temperature and centrifuged at 
3,000 rpm for 5 minutes at 4ºC to pellet the cell debris. Cleared supernatant was 
collected and mixed with equal volume of 50% (w/v) sucrose to produce rHRSV 
P0 stock, which were stored at -80ºC. 
 
2.2.3 Plaque pick method of recovering passage 1 virus 
Virus was recovered by the method described in section 2.2.2, but when 
over 30 infected cells were found in a single plaque, these infected cells were 
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scraped and collected using a p200 micropipette and OptiMEM (30 µl). The plaque 
suspension was used to infect 105 HEp-2 cells in a 24-well plate for rHRSV 
passage 1 infection.  
 
2.2.4 rHRSV passage  
2 x 105 HEp-2 cells were put into 6 wells of 6-well plate with of growth 
medium (2 ml) and each well received varying volume of virus (0.4 µl, 3.2 µl, 4 µl, 
12 µl, 40 µl) or left uninfected. Growth medium was replaced daily. When multiple 
wells have reached over 80% infectivity, the supernatant from the well with the 
least amount of input virus with over 80% infectivity was collected. This virus was 
used to repeat the 6 well dilution passage as described above until P2 or P3. These 
stocks were titered by tissue culture infectious dose 50 (TCID50) assay (section 
2.2.6) and used for the generation of stock virus. 
 
2.2.5 rHRSV stock generation 
In a T75 flask, 5 x 106 HEp-2 cells were infected with titered virus at an MOI 
of 0.02. Growth medium was replaced daily. When extensive cell monolayer 
disruption was observed, cells were scraped and collected with the supernatant. 
Supernatant was centrifuged at 3,000 rpm for 5 minutes at 4ºC and the cleared 
supernatant was mixed with equal volume of 50% (w/v) sucrose to produce the 
stock virus. Stock virus was stored at -80ºC. 
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2.2.6 rHRSV titer determination: TCID50 assay 
Virus was diluted 1:10 (10-1) in OptiMEM (1 ml) in triplicate. Each of the 
triplicate 1:10 dilution was serially diluted (1:10) seven times. Each dilution (200 µl) 
was added to quadruplicate wells of 96-well plates, which contained 2 x 104 Vero 
cells in each well. Cells were observed by phase and UV microscopy 7 days post-
infection (d.p.i.) and HRSV infected Vero cells were counted for each well. The 
titer in TCID50/ml was calculated using Reed and Muench 50% endpoint method 
(Reed and Muench, 1938). 
 
2.2.7 rHRSV titer determination: immunoplaque assay 
For each virus to be titered, 12 wells were plated with 1.5 x 105 cells HEp-2 
cells the day before the assay was set up. Virus was diluted 1:10 (10-1) in OptiMEM 
(250 µl) and serial dilution (1:10) was carried out five times in duplicate. Growth 
medium from the HEp-2 cells were removed and 200 µl of each dilution (10-1 to 
10-6) was added. Infections were carried out in 37ºC 5% (v/v) CO2 for an hour. 
Inoculum was removed and replaced with 0.8% (w/v) methylcellulose solution 
overlay (1 ml). 0.8% (w/v) methylcellulose solution was made using sterilized 
methylcellulose (Sigma-Aldrich) dissolved in HEp-2 growth medium (section 
2.1.2). Cells were kept at 37ºC with 5% (v/v) CO2 for at least 2 days and the 
plaques were observed by UV microscope. When the plaques became easily 
identifiable (3 to 4 d.p.i.), the overlay was removed and the cells were fixed with 
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80% (v/v) methanol (Sigma-Aldrich) at 4ºC for 30 minutes and removed. Methanol 
fixation step was repeated once more. Dried milk powder was mixed into DPBS to 
generate 5% (w/v) milk solution to be used as blocking buffer.  Cells were rinsed 
with ddH2O four times and blocking buffer (1 ml) was added. The plate of cells was 
rocked for 1 hour and cells were rinsed with ddH2O three times. Each well of cells 
received 1:200 goat polyclonal anti-RSV antibody (200 µl) (Abcam) in blocking 
buffer and plate was incubated at room temperature with rocking for 1 hour. 
Antibody was removed and cells were rinsed 3 times with ddH2O. Cells received 
1:1000 rabbit anti-goat HRP (200 µl) (Abcam) in blocking buffer and incubated at 
room temperature for 1 hour with rocking. Antibody was removed and cells were 
rinsed three times with ddH2O. Peroxidase substrate stock was made by dissolving 
4-chloronaphthol (Pierce) in ethanol at 3 mg/ml concentration. Immediately before 
use, the stock solution was diluted 1:10 in with PBS (10 ml) and 3% (v/v) hydrogen 
peroxide (0.1 ml) (Sigma-Aldrich). Diluted peroxidase solution (200 µl) was added 
to the cells and incubated for 15 minutes on a rocker at room temperature. 
Reaction was stopped by rinsing the cells with ddH2O. Plaque forming units (p.f.u.) 
per ml was calculated for each set of duplicate and averaged to determine the titer. 
 
2.2.8 Multistep growth analysis of rHRSV 
For each time point assayed, 3 x 105 HEp-2 cells were infected with rHRSV 
at an MOI of 0.2. The total volume of cell/virus mix was equal to 3 ml for each time 
point. Infected cells (1 ml) were added to 24-well plate in triplicate. At each time 
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point, 50% (w/v) sucrose was added to three wells of infected HEp-2 cells at an 
equal volume to the growth medium. The cells were stored at -80ºC. This process 
was repeated for triplicate wells at each time point. After the collection of last time 
point, all samples were defrosted and supernatants were used to set up TCID50 
assay in Vero cells (section 2.2.6).  
 
2.2.9 Microneutralization assay of rHRSVB05EGFP(5) 
Six hours prior to infection, 2 x 104 Vero cells were plated in 3 wells of 96-
well plate per dilutions of human intravenous immunoglobulin (IVIG) (CSL Behring) 
or human serum (Atlanta Biologicals) being tested. Cells were incubated at 37ºC, 
5% (v/v) CO2. Dilutions of IVIG or human serum were made in OptiMEM. A 
rHRSVB05EGFP(5) stock was made to contain 300 p.f.u. of virus per 50 µl. 
IVIG/human serum dilution (50 µl)  was added to 300 p.f.u. virus in triplicate. This 
mixture was incubated at 37ºC for 1 hour. The growth medium on Vero cells were 
removed and IVIG/human serum treated virus (100 µl) was added. Cells were 
incubated at 37ºC, 5% (v/v) CO2 for 30 minutes before the plate was manually 
agitated. Cells were incubated for an additional 30 minutes and supernatant was 
removed. To each well of cells, 0.8% (w/v) carboxymethylcellulose growth medium 
solution (100 µl) was added. Cells were observed using UV microscopy at 1 d.p.i. 
Foci of infection were counted and p.f.u. per ml was calculated. 
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2.2.10 Immunoblot analysis  
Transfected or infected cells were treated with 4x Laemmli buffer (Boston 
BioProducts), Halt protease inhibitor cocktail (Thermo Fisher Scientific), and EDTA 
(Thermo Fisher Scientific). DPBS was added to each well of cells and stored 
in -20ºC. After two freeze-thaw cycles to lyse the cells, samples were collected into 
microcentrifuge tubes and the DNA was sheared hydrodynamically. Laemmli 
buffer (5 µl) and NuPAGE reducing agent (1.5 µl) (Thermo Fisher Scientific) were 
added to an aliquot (10 µl) of the cell lysate and was heated at 70ºC for 10 minutes. 
Cell lysates were loaded onto NuPAGE 10% Bis-Tris protein gel (Thermo Fisher 
Scientific) and the proteins were separated by gel electrophoresis using NuPAGE 
MOPS SDS running buffer (Thermo Fisher Scientific). Proteins were transferred to 
a nitrocellulose blot using the iBlot dry blotting system (Thermo Fisher Scientific) 
at 20V for 7 minutes and 10 seconds. PBS-T solution was produced by 
supplementing 1x PBS with 0.1% (v/v) Tween-20. Blot was rinsed with PBS-T and 
blocked using 5% (w/v) milk solution for 18 hours at 4ºC. After the detection of 
protein of interest with specific primary and secondary antibodies (Appendix 2), 
blot was exposed and image was obtained by Odyssey CLx Imaging System 
(LI-COR) using LI-COR Image Studio software (LI-COR).  
 
2.2.11 Indirect immunofluorescence  
Growth medium was removed from the cells and cells were rinsed with 
DPBS. DPBS was removed and 10% (v/v) buffered formalin (Fisher Scientific) was 
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added to each well of cells at room temperature for 10 minutes to fix the cells. 
Fixative was removed and cells were rinsed with DPBS. Cells were permeabilized 
using 0.5% (v/v) Triton X-100 in DPBS (500 µl) and incubated at room temperature 
for 15 minutes. Cells were rinsed and blocked using Image-iT FX signal enhancer 
ready probes reagent (Molecular Probes) at room temperature for 30 minutes and 
the reagent was removed. Cells were rinsed and treated with BlockAid blocking 
solution (Molecular Probes) at room temperature for 30 minutes and the blocking 
solution was removed. Cells were rinsed with DPBS. Primary antibody dilution 
(Appendix 2) in BlockAid blocking solution was added to cells and was incubated 
at 37ºC for 1 hour. Cells were rinsed with DPBS and secondary antibody dilution 
(Appendix 2) in BlockAid blocking solution was added. Cells were rinsed with 
DPBS and coverslips on which cells were adhered were mounted onto glass slides 
(VWR) using VECTASHIELD HardSet Antifade Mounting Medium with 
4’,6-diamidinmo-2-phenylindole (DAPI) (Vector Laboratories).  
 
2.2.12 Live cell imaging preparation for confocal laser scanning microscopy 
(CLSM) 
Growth medium was removed from cells in 35 mm µ-Dish glass bottom plate 
(Ibidi) and primary antibody dilution (Appendix 2) in growth medium was added. 
Cells were incubated at room temperature for 10 minutes and the antibody mix 
was removed. Cells were rinsed with DPBS and live cell imaging growth medium 
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(1 ml) (section 2.1.2), 3 drops of NucBlue live probe (Molecular Probes), and 
0.1mM of Trolox (Vector Laboratories) were added. 
 
2.3. Molecular biology 
2.3.1 Sequence analysis 
Clone/primer design, computer clone generation, and polymerase chain 
reaction/restriction digestion plans were completed using SeqBuilder software 
(DNASTAR). Sequence alignment and analysis were completed using SeqMan 
Pro software (DNASTAR).  
 
2.3.2 Molecular biology equipment 
DNA concentration was measured using NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). Bacterial liquid culture incubation 
for DNA preparation was completed in MaxQ 5000 incubator shaker (Thermo 
Fisher Scientific). Mixing samples by vortex agitation was completed using Vortex-
2 Genie (Scientific Industries). Samples in microcentrifuge tubes were centrifuged 
using benchtop centrifuge 5424 (Eppendorf) or benchtop centrifuge 5417C 
(Eppendorf). To heat and cool samples in microcentrifuge tubes, Thermomixer R 
heat block (Eppendorf) was used. 
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2.3.3 Restriction digestion 
Restriction enzymes were purchased from New England Biolabs (NEB). 
Digestion contained at least 1 µg of the DNA to be cut, enzyme dependent buffers 
at 1x, at least 10 units of each enzyme for the reaction, and nuclease free water 
(Invitrogen). The reaction mix was incubated at the temperature provided by the 
manufacturer for 1 to 24 hours.  
 
2.3.4 DNA gel electrophoresis 
DNA fragments were separated by gel electrophoresis in 1% (w/v) agarose 
gel containing ethidium bromide (Sigma-Aldrich) for DNA fragments larger than 
500 bp and 2% (w/v) agarose gel containing ethidium bromide for smaller DNA 
fragments. DNA fragments in gel were visualized and analyzed using MultiImage 
II gel imager (Alpha Innotech). DNA fragment in the gel was excised using gel 
extractor (USA Scientific) and the DNA was purified using QIAQuick gel extraction 
kit (QIAGEN) according to the manufacturer’s specifications. 
 
2.3.5 Polymerase chain reaction (PCR) 
Primers (Appendix 1) were synthesized by Sigma-Aldrich. PCR reactions 
were carried out using Phusion high-fidelity DNA polymerase (NEB) and Phusion 
HF buffer. The reaction mix was set up according to the manufacturer’s 
specifications and 10 to 100 ng of template DNA was used. C1000 thermocycler 
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(BioRad) was used to set up cycle conditions according to the Phusion enzyme 
manufacturer’s specifications. 
 
2.3.6 Gibson assembly 
Gibson assembly reaction was set up according to the manufacturer’s 
(NEB) specifications to allow assembly of multiple DNA fragments with 15 to 40 nt 
 overlaps. The 20 µl reaction contained Gibson assembly master mix (10 µl), 0.01 
to 0.25 pM of vector, 3 times the vector amount of each of the insert. The reaction 
was incubated at 50ºC for 1 hour. 
 
2.3.7 Ligation 
Gel purified vector was treated with Antarctic phosphatase according to the 
manufacturer’s specification using 5 units of the enzyme. T4 DNA ligase (400 U) 
(NEB) was used to ligate vector and insert according to the manufacturer’s 
specification. For all ligations, vector to insert ratio was maintained at 1:3. The 
reaction was incubated at room temperature for at least 2 hours or at 16ºC for 18 
hours.  
 
2.3.8 Bacterial transformation 
DH5α chemically competent cells (NEB) stored in -20ºC were thawed out 
on ice and aliquoted into 8 – 15 µl aliquots. Ligation/Gibson assembly reaction 
(1 – 5 µl) or plasmid (10 – 50 ng) was added to the cells. Cells were left on ice for 
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30 minutes and incubated at 42ºC water bath for 90 seconds. Cells were incubated 
in ice for 5 minutes, SOC medium (100 µl) (NEB) was added, and incubated at 
37ºC for at least 20 minutes. Cells were plated onto an LB agar (BD Biosciences) 
plate containing ampicillin (Sigma-Aldrich) or kanamycin (Sigma-Aldrich) as 
determined by the antibiotic resistance of the clone. The plates were incubated at 
30ºC for at least 24 hours (plasmids containing HRSV G protein gene) or at 37ºC 
for at least 12 hours.  
 
2.3.9 Small scale plasmid DNA preparation 
A single colony from a transformation (section 2.3.8) was picked and added 
into LB broth (3 ml) (BD biosciences) containing 100 µg/ml ampicillin (Sigma-
Aldrich) or 50 µg/ml kanamycin (Sigma Aldrich) depending on the antibiotic 
resistance of the clone. The liquid culture was incubated in a shaker at 37ºC for at 
least 18 hours for plasmids smaller than 12,000 bp in length and 30ºC for at least 
24 hours for longer plasmids. Bacterial culture was removed from the shaker, 
culture (1.5 ml) was added to a microcentrifuge tube, centrifuged at 13,000 rpm for 
1 minute in a benchtop centrifuge. Most of the supernatant was removed and the 
pellet was suspended in remaining supernatant. TENS solution was produced just 
prior to the plasmid preparation using 20 mM TRIS with 2 mM EDTA and 0.2 M 
NaOH with 1% (w/v) SDS. To the bacterial suspension, TENS solution (300 µl) 
and 3M sodium acetate (150 µl) (Sigma-Aldrich) were added and mixed using a 
vortex. Samples were centrifuged at 13,000 rpm for 5 minute in a benchtop 
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centrifuge and the supernatant was transferred to microcentrifuge tubes containing 
4°C 100% ethanol and mixed by inversion of the tubes. The samples were 
centrifuged at 13,000 rpm for 5 minutes and 70% (v/v) ethanol (400 µl) was added. 
Samples were centrifuged at 13,000 rpm for 3 minutes and the DNA pellet was 
dried. Pellet was suspended in 10 mM TRIS buffer (Sigma-Aldrich) supplemented 
with 25 µg/ml RNAse A (Sigma-Aldrich).  
 
2.3.10 Large scale plasmid preparation 
A single colony from a transformation (section 2.3.8) or 0.5 ml of a small 
scale bacterial liquid culture (section 2.3.9) was added to LB broth (3 ml) containing 
100 µg/ml ampicillin (Sigma-Aldrich) or 50 µg/ml kanamycin (Sigma-Aldrich) 
depending on the antibiotic resistance of the plasmid. This culture was incubated 
at 30ºC for plasmids longer than 12,000 bp in length or 37 ºC for at least 6 hours 
for plasmids shorter than 12,000 bp in length. Liquid culture was added to LB broth 
(200 to 400 ml) containing ampicillin (Sigma-Aldrich) or kanamycin 
(Sigma-Aldrich). This culture was incubated at 30ºC for 26 hours for plasmids 
longer than 12,000 bp in length or 37ºC for 16 hours for plasmids shorter than 
12,000 bp in length in a shaker. Liquid culture was put into a bottle and centrifuged 
at 4,650 rpm in 4ºC for 30 minutes in Allegra X-15R centrifuge (Beckman Coulter) 
to pellet the bacterial cells. Plasmids were purified using HiSpeed Plasmid Maxi 
Kit (Qiagen) and the manufacturer’s specification.  
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2.3.11 Sanger dideoxy sequencing 
Primers (Sigma-Aldrich) used for sequencing are listed in Appendix 1. The 
Sanger dideoxy sequencing was completed by GENEWIZ (New Jersey, USA). 
Results were provided as electrochromatograms which were used to align with the 
expected sequence using SeqMan Pro software (section 2.3.1). 
 
2.3.12 RNA isolation  
To prepare the lysate for RNA isolation, virus stock (250 µl) was mixed with 
TRIzol LS (750 µl) (Thermo Fisher Scientific) by inversion of the tube and samples 
were incubated at room temperature for 5 minutes. Chloroform (200 µl) (Sigma-
Aldrich) was added and samples were incubated at room temperature for 3 
minutes. Sample were centrifuged at 13,000 rpm in 4ºC. The aqueous phase was 
removed and was used for RNA isolation according to the TRIzol LS 
manufacturer’s specification.  
 
2.3.13 DNase treatment of RNA samples 
To remove DNA from purified RNA samples, TURBO DNase buffer (2 µl) 
(Life Technologies) and TURBO DNase (2 U) (Life Technologies) were added to 
RNA samples (20 µl). Samples were incubated at 37°C for 30 minutes and DNase 
inactivation reagent (2 µl) (Life Technologies) was added and incubated at room 
temperature for 5 minutes. Samples were centrifuged at 11,000 rpm for 
1.5 minutes and supernatant was collected. 
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2.3.14 Sequencing HRSV full-length genome 
RNA samples were used for cDNA synthesis using SuperScript III reverse 
transcriptase (Invitrogen) and HRSV forward primers (Table 2.1), which generated 
overlapping cDNA fragments. Reactions were set up according to the 
SuperScript III manufacturer’s specification. Using the cDNAs generated from 
RNA or a full-length antigenomic plasmid, multiple overlapping amplicons of HRSV 
genome was generated by PCR (section 2.3.5). Phusion High-Fidelity PCR kit 
(New England Biolabs) and gene specific primers (Table 2.2) were used for 
amplification using the Phusion High-Fidelity PCR kit manufacturer’s 
specifications. The presence of amplicons of expected sizes were verified by gel 
electrophoresis in 1% agarose gel and the DNA fragment was purified (section 
2.3.4). The purified DNA fragments were used for Sanger dideoxy sequencing 
(section 2.3.11) usinG protein gene specific primers (Table 2.3) 
 
2.3.15 Rapid amplification of cDNA ends (RACE) for rHRSV leader  
Total RNA isolated from virus stock (section 2.3.12) was polyadenylated on 
the Le side using E. coli polyA polymerase (NEB). Reaction consisted of RNA 
(7.375 µl), 10x SuperScript III RT buffer (1.25 µl) (Invitrogen), 25 mM MgCl2 (2.5 
µl) (NEB), 10 mM ATP (0.625 µl) (Invitrogen), RNAseOUT (40 U) (NEB), and PolyA 
polymerase (1.25 U) (NEB). Reactions were incubated at 37ºC for 30 minutes and 
65ºC for 20 minutes. Polyadenylated RNA was used as a template for cDNA  
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cDNA name Primer
1 priHRSV-A10-42+
2 priHRSV-A10-5046+
3 priHRSV-A10-12600+
cDNA name Primer
1 priHRSV-B05-33+
1b priHRSV-B05-2554+
2 priHRSV-B05-5087+
3 priHRSV-B05-10127+
B
A
Table 2.1: Primers used to amplify HRSVA11 and HRSVB05 cDNA fragments
from RNA samples. (A) Three cDNA fragments (1, 2, 3) were generated from
HRSVA11 RNA samples and (B) four cDNA fragments (1, 1b, 2, 3) were
generated from HRSVB05 RNA samples using the primers listed. The
sequences corresponding to each primer are listed in Appendix 1.
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Table 2.2A: Primers used to amplify overlapping amplicons from HRSVA11
cDNA. Multiple amplicons were generated using the cDNA template listed in
Table 2.1a. * amplicons generated instead of amplicon B only if the genome
contained EGFP ATU. The sequences corresponding to each primer are listed
in Appendix 1.
Amplicon cDNA template Forward primer Reverse primer
A 1 priHRSV-A11-42+ priHRSV-A10-2617-
B1* 1 priHRSV-A10-2558+ priHRSV-A10-3285-
B2* 1 priEGFP-685+ priHRSV-A10-5095-
B 1 priHRSV-A10-2558+ priHRSV-A10-5095-
C 2 priHRSV-A10-5046+ priHRSV-A10-7607-
D 2 priHRSV-A10-7577+ priHRSV-A10-10150-
E 3 priHRSV-A10-10076+ priHRSV-A10-10150-
F 3 priHRSV-A10-12600+ priHRSV-A10-15171-
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Table 2.2B: Primers used to amplify overlapping amplicons from
HRSVB05 cDNA. Multiple amplicons were generated using the cDNA template
listed in Table 2.1b. * amplicons generated instead of amplicon B only if the
genome contained EGFP or dTom ATU. The sequences corresponding to each
primer are listed in Appendix 1.
Amplicon cDNA template Forward primer Reverse primer
A 1
priHRSV-B05-33+ priHRSV-B05-2579-
B1a* 1b
priHRSV-B05-2554+ priXFP-698-
B1b* 1b
priXFP-22+ priHRSV-B05-3767-
B1 1
priHRSV-B05-2554+ priHRSV-B05-3767-
B2 1
priHRSV-B05-3698+ priHRSV-B05-5650-
C 2
priHRSV-B05-5087+ priHRSV-B05-7609-
D 2
priHRSV-B05-7574+ priHRSV-B05-10145-
E 3
priHRSV-B05-10127+ priHRSV-B05-12687-
F 3
priHRSV-B05-12609+ priHRSV-B05-15214-
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Table 2.3A: Primers used to sequence each amplicon of HRSVA11 cDNA.
Amplicons generated using primers from Table 2.2A were used for Sanger
sequencing reactions with primers listed. The sequences corresponding to
each primer are listed in Appendix 1.
Template 
amplicon
Primer
A priHRSV-A10-278-
A priHRSV-A10-103+
A priHRSV-A10-913+
A priHRSV-A10-1569+
A priHRSV-A10-1946+
A priHRSV-A10-2576+
B/B1 priHRSV-A10-2924-
B/B1 priHRSV-A10-2803+
B/B1 priHRSV-A10-3203+
B1 priEGFP-339+
B1 priEGFP-591+
B/B2 priHRSV-A10-3285-
B/B2 priHRSV-A10-3845+
B/B2 priHRSV-A10-4390+
C priHRSV-A10-5786-
C priHRSV-A10-5305+
C priHRSV-A10-6231+
Template 
amplicon
Primer
C priHRSV-A10-6707+
C priHRSV-A10-7158+
D priHRSV-A10-8281-
D priHRSV-A10-8168+
D priHRSV-A10-8617+
D priHRSV-A10-9102+
D priHRSV-A10-9781+
E priHRSV-A10-10771-
E
priHRSV-A10-
10401+
E
priHRSV-A10-
11023+
E
priHRSV-A10-
11648+
E
priHRSV-A10-
12273+
F priHRSV-A10-13291-
F
priHRSV-A10-
12910+
F
priHRSV-A10-
13537+
F
priHRSV-A10-
14144+
F
priHRSV-A10-
14854+
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Table 2.3B: Primers used to sequence each amplicon of HRSVB05 cDNA.
Amplicons generated using primers from Table 2.2B were used for Sanger
sequencing reactions with primers listed. The sequences corresponding to
each primer are listed in Appendix 1.
Template 
amplicon
Primer
A priRSV-B-285R 
A priHRSV-B05-169+ 
A priHRSV-B05-739+
A priHRSV-B05-1262+
A priHRSV-B05-1745+
A priHRSV-B05-2225+
B1/B1a priHRSV-B05-3084-
B1/B1a priHRSV-B05-2916+
B1a priXFP22+
B1b priXFP698-
B1/B1b priRSV-B-3267+
B2 priHRSV-B05-4109-
B2 priHRSV-B05-3936+
B2 priHRSV-B05-4524+
B2 priHRSV-B05-5014+
C priHRSV-B05-5599-
C priHRSV-B05-5555+
Template 
amplicon
Primer
C priHRSV-B05-6251+
C priHRSV-B05-6743+
C priHRSV-B05-7435+
D priHRSV-B05-7870-
D priHRSV-B05-7788+
D priHRSV-B05-8230+
D priHRSV-B05-8734+
D priHRSV-B05-9476+
E priHRSV-B05-10581-
E
priHRSV-B05-
10309+
E
priHRSV-B05-
10747+
E
priHRSV-B05-
11757+
E
priHRSV-B05-
12230+
F priHRSV-B05-13104-
F
priHRSV-B05-
12815+
F
priHRSV-B05-
13598+
F
priHRSV-B05-
14176+
F
priHRSV-B05-
14604+
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synthesis using SuperScript III reverse transcriptase (Invitrogen) and 
priAdaptor-dT17 (Appendix 1) using manufacturer’s specifications. cDNA was 
purified using QIAquick PCR purification kit (QIAGEN) according to the 
manufacturer’s specifications. Purified cDNA was used as a template for 
amplification of the leader end of the genome using Phusion High Fidelity 
polymerase (NEB), priAdaptor, priAdaptor-dT17, and gene specific reverse primer. 
Amplicon was verified by gel electrophoresis and the DNA fragment was gel 
extracted (section 2.3.4). The purified amplicon was used for Sanger dideoxy 
sequencing using a gene specific reverse primer. 
 
2.3.16 Rapid amplification of cDNA ends (RACE) for rHRSV trailer 
RNA isolated from virus stock (section 2.3.12) was used as a template for 
cDNA synthesis using SuperScript III reverse transcriptase (Invitrogen) and gene 
specific forward primers using SuperScript III manufacturer’s specifications. cDNA 
was purified using QIAquick PCR purification kit (QIAGEN) according to the 
manufacturer’s specifications. Purified cDNA was tailed using terminal transferase 
(NEB) and dATP. The reaction contained cDNA (30 µl), 10X terminal transferase 
buffer (5 µl) (NEB), 2.5 mM CoCl2 (5 µl) (NEB), 10 mM dATP (1 µl) (Invitrogen), 
terminal transferase (10 U) (NEB), and nuclease free water (8.5 µl). Reaction was 
carried out at 37ºC for 30 minutes and heat inactivated at 70ºC for 10 minutes. 
Tailed cDNA was purified using QIAquick purification kit (QIAGEN) according to 
the manufacturer’s specifications. End of the HRSV cDNA was amplified by PCR 
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using purified tailed cDNA, Phusion High Fidelity polymerase (NEB), priAdaptor, 
priAdaptor-dT17, and a gene specific forward primer. The size of the amplicon was 
verified by gel electrophoresis and the DNA fragment was gel extracted (section 
2.3.4). purified amplicon was used for Sanger dideoxy sequencing using a gene 
specific forward primer. 
 
2.3.17 RNA ligation  
RNA isolated from virus stock (section 2.3.12) was denatured at 90ºC for 3 
minutes and was ligated using T4 RNA ligase I kit (NEB). Reaction containing 
denatured RNA (8 µl), 10x T4 RNA ligation reaction buffer (2 µl) (NEB), RNase 
inhibitor (0.5 µl) (NEB), 50% PEG 8000 (4 µl) (NEB), 10mM ATP (0.1 µl) (NEB), 
T4 RNA ligase (10 U) (NEB), and nuclease free water (5.4 µl) was incubated at 
16ºC for 18 hours and was heat inactivated at 95ºC for 5 minutes. Ligated RNA 
was purified using RNeasy RNA purification kit (QIAGEN) according to the 
manufacturer’s specifications.  
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CHAPTER 3: HRSV SUBTYPE DIFFERENCES 
 
3.1 Generation of plasmids to express HRSVA11 proteins 
 To recover rHRSV, HEp-2 cells are transfected with a full-length 
antigenomic plasmid and plasmids which express the HRSV N, P, M2-1, and L 
proteins (section 1.8). Plasmids expressing HRSVA11 N, P, and M2-1 proteins were 
available. A plasmid expressing HRSVA11 L was constructed. 
  
 Plasmid encoding HRSVA11 L protein, pCG-HRSVA11L, was generated using 
pscCG-HRSVA11LΔBam (Figure 3.1A) provided by Dr. Sham Nambulli at Boston 
University (BU). The subclone (sc) was digested with Bam HI (section 2.3.3), the 
5,434 bp DNA fragment was gel extracted (section 2.3.4), and dephosphorylated 
with Antarctic phosphatase to generate a linear vector (section 2.3.7). A plasmid, 
pHRSVA11, containing the complete antigenome of HRSVA11 was generated by Dr. 
Ken Lemon at the Queen’s University in Belfast (QUB). Large scale plasmid 
preparation of pHRSVA11 was optimized to yield higher concentration of plasmid 
by adjusting the E. coli culture growth conditions (section 2.3.10). pHRSVA11 
(Figure 3.1B) was digested with Bam HI and the 5,529 bp DNA fragment was gel 
extracted to generate an insert. One to three ratio of vector and insert were ligated 
with T4 DNA ligase (section 2.3.7) and the ligation was used to transform E. coli 
DH5α competent cells (section 2.3.8). This ratio was kept constant for all following 
transformations from ligated product. The transformed cells were plated onto LB  
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agar plates containing ampicillin. Six colonies were amplified in liquid culture 
containing ampicillin and plasmids were isolated by small scale plasmid 
preparation (section 2.3.9). Plasmids were screened by diagnostic restriction 
digestion (section 2.3.3) to examine if ligation was successful and three plasmids 
were identified which contained the insert. Liquid culture containing ampicillin was 
inoculated with a single bacterial clone. This culture was used to isolate 
pCG-HRSVA11-L by large scale plasmid preparation (section 2.3.10). Plasmid was 
digested using Ava I and Nco I restriction enzymes (section 2.3.3). Presence of 
3217, 2822, 2465, 685, 632, 583, 444, and 115 bp DNA fragments was confirmed 
by gel electrophoresis (Figure 3.2A). Restriction digestion is presented as an 
example and will not be shown for other cloning results in this thesis. This plasmid 
was sequence verified by Sanger dideoxy sequencing using pripCG+, priRSV-
A10-8489+, priRSV-A10-9102+, priRSV-A10-10401+, priRSV-A10-11023+, 
priRSV-A10-11648+, priRSV-A10-12273+, priRSV-A10-12910+, 
priRSV-A10-13537+, priRSV-A10-14144+, and, pripCG-b (Appendix 1) to check 
the sequence across the Ava I sites used for cloning (Figure 3.2B) and across the 
L gene (data not shown). Sequences were aligned with the pCG-HRSVA11L (Figure 
3.1C) computer clone using DNASTAR SeqMan Pro software and no spurious 
mutations were found. 
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3.2 Generation of pHRSVA11EGFP(5) 
 The sequence of HRSVA11 strain was obtained directly from a clinical 
sample (Dr. Ken Lemon, QUB). Amplicons were used to construct an antigenomic 
plasmid, pHRSVA11 (Dr. Ken Lemon, QUB). This plasmid was used to generate, 
pHRSVA11EGFP(5), which would be used to recover an rHRSVA11 which expresses 
EGFP. This recombinant HRSV would allow comparisons to be made between the 
two subtypes of HRSV, using rHRSVB05EGFP(5) (Lemon et al., 2015). Previous 
studies demonstrated there were significant difficulties cloning plasmids containing 
G protein genes of HRSV, therefore a subclone lacking these sequences, 
pscHRSVA11EGFP(5)ACD, was constructed. pscHRSVA11ACD lacks 3,157 bp 
fragment B encoding from the end of SH gene to beginning of L gene (Dr. Ken 
Lemon, QUB). This subclone was used to insert an ATU containing EGFP gene 
sequence to reduce the difficulties associated with growing full-length plasmids 
containing sequences of G protein gene. pscHRSVA11ACD (Figure 3.3A) was 
digested with Ava I and the 12,666 bp DNA fragment was gel extracted (section 
2.3.4) to produce the linear vector. pMK-HRSVA11EGFP(5) (Figure 3.3B) was 
synthesized by GeneArt to contain the ATU containing EGFP gene sequence after 
P gene of HRSVA11 antigenome flanked by HRSVA11 sequences up to two Ava I 
sites. pMK-HRSVA11EGFP(5) was digested with Ava I, the 2,556 bp DNA fragment 
was gel extracted (section 2.3.4), and dephosphorylated with Antarctic 
phosphatase to produce the insert. Vector and insert were ligated using T4 DNA  
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ligase (section 2.3.7) and E. coli DH5α competent cells were transformed with one 
fourth of the ligation (section 2.3.8). The transformed cells were plated onto an LB 
agar plate containing ampicillin. Six colonies were amplified in liquid culture 
containing ampicillin and plasmids were isolated by small scale plasmid 
preparation (section 2.3.9). Plasmids were screened by diagnostic restriction 
digestion to examine if ligation was successful (section 2.3.3). Two plasmids 
shown to contain the insert were sequenced by Sanger dideoxy sequencing using 
priRSV-A10-2576+, priRSV-A-2637+, priRSV-A-3528+, priHRSV-A10-8639-, 
priRSV-A-9051-, priRSV-A-14854+, priHRSV-A10-15838+, and priEGFP591+ 
(Appendix 1) across the insert (section 2.3.11). Sequences were aligned with the 
computer clone of pscHRSVA11EGFP(5)ACD (Figure 3.3C) using DNASTAR 
SeqMan Pro software and no spurious mutations were identified (Figure 3.4).  
 
 A full-length HRSVA11 antigenomic plasmid with an ATU encoding EGFP, 
pHRSVA11EGFP(5), was constructed by inserting in HRSVA11 fragment B into 
pscHRSVA11EGFP(5)ACD. pscHRSVA11EGFP(5)ACD (Figure 3.3C) was digested 
with Xho I and Bsu 36I restriction enzymes (section 2.3.3) to generate 15,255 bp 
linear vector. pHRSVA11 (Figure 3.5A) was digested with Xho I and Bsu 36I to 
generate a 4,104 bp insert. Vector and insert were gel extracted (section 2.3.4), 
ligated using T4 DNA ligase (section 2.3.7), and ligation was used to transform 
E. coli DH5α competent cells (section 2.3.8). Transformed cells were plated onto 
LB  agar plates containing ampicillin. Eleven colonies were amplified in liquid 
 50 
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culture and plasmids were isolated by small scale plasmid preparation (section 
2.3.9). Plasmids were examined by diagnostic restriction digestion and the 
presence of insert was confirmed in one plasmid. Sequence surrounding Xho I and 
Bsu 36I restriction sites in this plasmid was verified by Sanger dideoxy sequencing 
using priRSV-A10-4390+ and priHRSV-A10-8639- (Appendix 1) (section 2.3.11). 
Sequences were aligned with the computer clone of pHRSVA11EGFP(5) using 
DNASTAR SeqMan Pro software and no spurious mutations were observed 
across the two restriction sites (data not shown). Sequence verified 
pHRSVA11EGFP(5) (Figure 3.5B) plasmid was used to transform E. coli DH5α 
competent cells (section 2.3.8) and one colony was amplified in liquid culture 
containing ampicillin and plasmids were isolated by large scale plasmid 
preparation (section 2.3.9). Restriction digestions (section 2.3.3) were set up for 
the plasmid with Ava I, Bam HI, and Spe I enzymes and Xho I and Bsu 36I 
enzymes to confirm that the restriction sites are intact and that the sizes of DNA 
fragments generated were as expected. Sequence of the insert was verified by 
Sanger dideoxy sequencing (section 2.3.11) using priRSV-A10-4390+, 
priHRSV-A10-4426+, priRSV-A10-5305+, priRSV-A10-5761+, 
priHRSV-A10-5786-, priRSV-A10-6231+, and priHRSV-A10-8168+ (Appendix 1). 
Sequences were aligned with pHRSVA11EGFP(5) computer clone using 
DNASTAR SeqMan Pro software and no spurious mutations were identified at the 
restriction sites (Figure 3.5C) or in HRSV G and F glycoprotein genes. This is 
important since mutations have occurred commonly when cloning plasmids 
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containing these HRSV sequences (data not shown). The remainder of the 
HRSVA11 sequence was sequenced using the HRSVA11 full-length genome 
sequencing protocol (section 2.3.14) and no spurious mutations were present. 
 
3.3 Recovery of rHRSVA11 and rHRSVA11EGFP(5) 
 rHRSVA11 had been previously recovered using pHRSVA11 and plasmids 
expressing HRSVB05 N, P, M2, and L proteins, but it has not been recovered using 
plasmids derived from HRSVA11. The standard rHRSV rescue method (section 
2.2.2) was used to recover rHRSVA11 in HEp-2 cells and passaged four times 
(section 2.2.4, 2.2.5). The primary rescue and the subsequent passages were 
observed by phase-contrast microscopy. HRSV causes CPE in vitro generating 
multinucleated syncytia, which round up, and become non-adherent. It was difficult 
to identify CPE in HEp-2 cell monolayers in primary rescue, as cells became 
overgrown (Figure 3.6A). However, in subsequent passages when small volume 
of the supernatant from the primary rescue was serially passaged (section 2.2.4), 
it was straightforward to distinguish foci of infection (Figure 3.6B). rHRSVA11 
passage 4 (P4) stock (Figure 3.6C) was collected (section 2.2.5) and titer of 
106.86 TCID50/ml was determined by TCID50 assay in Vero cells (section 2.2.6). 
Vero cells were chosen because HRSV CPE in Vero cells were more identifiable 
compared to in HEp-2 cells and gave more accurate titer (data not shown). 
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 Since rHRSVA11 recovery was successful, rHRSVA11EGFP(5) was 
recovered with the same protocol (section 2.2.2). Expression of EGFP was 
observed to identify infected cells. After primary rescue (Figure 3.7A) in which all 
transfected wells contained virus, this virus was passaged four times to produce 
the stock virus for experiments (Figure 3.7B). The titer of stock virus was 
determined to be 107.26 TCID50/ml in Vero cells.  
 
RNA was isolated (section 2.3.12) from stocks of rHRSVA11 and 
rHRSVA11EGFP(5). Virus specific RNA were reverse transcribed using gene 
specific primers (Table 2.1) to generate cDNA. From the viral cDNA, amplicons 
were generated to overlap across the 15 kb full-length genome, which was 
sequenced to check for any spurious mutations in the viral genome (section 
2.3.14). Rapid amplification of cDNA ends (RACE) protocol (section 2.3.15 and 
2.3.16) was used for amplifying the termini of the genome which was sequenced 
using priRSV-A10-278- and priHRSV-A11-14918+. Sequences obtained by 
Sanger dideoxy sequencing (section 2.3.11) were aligned to rHRSVA11 or 
rHRSVA11EGFP(5) sequences using DNASTAR SeqMan Pro software to identify 
any spurious mutations. In rHRSVA11 stock P4, there was a heterogenic population 
of sequences found at the first nucleotide of the viral genome. The expected 
adenine (A) was present, but approximately 30% of the population had a uracil (U) 
(shown as thymine (T)) at this position (Figure 3.8A). Another heterogeneous 
sequence  was found at nucleotide 3307 of rHRSVA11 genome and approximately 
 56 
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30% of the population had U to guanine (G) change at this position (Figure 3.8B). 
This was located in the M protein gene but did not change the amino. Two 
heterogeneous nucleotides were also present in rHRSVA11EGFP(5) stock P4. One 
was located at first nucleotide of the viral genome where there was less than 25% 
of the population with A to U change (Figure 3.8C). Finally, there was also a U to 
A change at nucleotide 7176 (T in the cDNA sequence) in approximately 50% 
population (Figure 3.8D). This would cause S509T amino acid change in the F 
glycoprotein. This rHRSVA11EGFP(5) stocks was used for following preliminary 
experiments. 
 
3.4 Generation of pHRSVB05dTom(5) 
 Generating two rHRSV expressing different fluorescent proteins would 
allow comparisons to be made in coinfection models, in vitro and in vivo. 
pHRSVB05dTom(5) was generated to allow recovery of a rHRSVB05 that expresses 
dTom, which can be used in coinfection model with rHRSVA11EGFP(5). 
pCG-dTom239 (Figure 3.9A) was generated by Dr. Linda Rennick (BU) to express 
dTom with an addition of five amino acid linker consisting of glycines and serines 
(GSGSG) at its terminus to adjust the protein to the length of EGFP (239 amino 
acids). dTom239 sequence was amplified from pCG-dTom239 by PCR (section 
2.3.5) using pridTom25+BssHII, which contains a Bss HII site upstream of dTom 
sequence, and pridTom240+PacI, which contains a Pac I site downstream of 
dTom  sequence  (Appendix 1). The 750 bp amplicon was purified by gel extraction 
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(section 2.3.4) (Appendix 1). The 750 bp amplicon was purified by gel extraction 
(section 2.3.4) and cloned into a TOPO vector using ZeroBlunt TOPO kit. One third 
of TOPO reaction was used to transform E. coli DH5α competent cells (section 
2.3.8) which was plated onto LB agar plates containing kanamycin. One colony 
was amplified in liquid culture containing ampicillin and plasmid was isolated by 
small scale plasmid preparation. Restriction digestion (section 2.3.3) with Eco RI 
restriction enzyme confirmed that the insert was present. TOPO-dTom239 (Figure 
3.9B) was digested with Pac I and Bss HII sequentially and the 733 bp DNA 
fragment was gel extracted (section 2.3.4) to generate the insert. Linear vector 
was generated by sequentially digesting pHRSVB05EGFP(5) (Figure 3.9C) with 
Pac I and Bss HII, gel extracting (section 2.3.4) the 18,524 bp DNA fragment, and 
dephosphorylating it with Antarctic phosphatase. Vector and insert were ligated 
using T4 DNA ligase (section 2.3.7) and E. coli DH5α competent cells were 
transformed with the ligation (section 2.3.8). Transformed cells were plated onto 
LB agar plates containing ampicillin. Twelve colonies were amplified in liquid 
culture which was used to isolate plasmids by small scale plasmid preparation. 
Three plasmids contained the insert when examined by diagnostic restriction 
digestion (section 2.3.3). These plasmids were sequence verified by Sanger 
dideoxy sequencing using priRSV2859F, pridTom25+BssHII, and 
pridTom240+PacI (Appendix 1) to check the sequence across the restriction sites 
used. Sequences were aligned with pHRSVB05dTom(5) (Figure 3.9D) computer 
clone using DNASTAR SeqMan Pro software and no spurious mutations were 
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found (data not shown). A single bacterial clone was amplified in liquid culture 
containing ampicillin and was used to isolate plasmid by large scale plasmid 
preparation. Restriction digestion (section 2.3.3) with Pac I and Bss HII restriction 
enzymes and with Bsr GI and Bst XI restriction enzymes were carried out. It 
confirmed the presence of expected sizes of DNA fragments suggesting no large 
insertions or deletions that occurred during the amplification in bacterial culture 
(data not shown). The restriction sites (Figure 3.10) and the insert within 
pHRSVB05dTom(5) was sequence verified by Sanger dideoxy sequencing using 
pridTom25+BssHII, pridTom240-PacI, priRSV-B-4476F, priRSV-B-4883F, 
priHRSV-B05-5385+, and priHRSV-B05-5873+ (Appendix 1). Sequences were 
was aligned with pHRSVB05dTom(5) computer clone using DNASTAR SeqMan Pro 
software and no spurious mutations were identified. 
  
3.5 Recovery of rHRSVB05dTom(5)  
 rHRSVB05dTom(5) was recovered using standard rHRSV rescue method  
(section 2.2.2). Four of six transfected wells during primary rescue (Figure 3.11A) 
showed signs of successful recovery of virus. rHRSVB05dTom(5) was passaged 
three times (Figure 3.11B) to produce P3 stock with 105.89 TCID50/ml titer in Vero 
cells. 
 
RNA was isolated from rHRSVB05dTom(5) stock (section 2.3.12). Virus 
specific RNA was reverse transcribed using gene specific primers (Table 2.1) to 
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generate viral cDNA. Using the cDNA generated as the template, amplicons were 
generated to overlap across the 15 kb full-length genome, which was sequenced 
(section 2.3.14). The ends of the genome were amplified by rHRSVB05 RACE 
method and sequenced (section 2.3.16) using priB05-204- and priB05-15063+. 
Sequences obtained by Sanger dideoxy sequencing were aligned to 
rHRSVB05dTom(5) cDNA computer clone using DNASTAR SeqMan Pro software 
to identify any spurious mutations. In the leader, 50% of the population showed A 
to U (T in cDNA) change at first nucleotide in the viral genome (Figure 3.12A).  
  
Minor peaks in electrochromatograms of sequences in the trailer showed a 
nucleotide shift of -1 after L GE (Figure 3.12B). This suggested an insertion of an 
A at the repeat of 6 A’s at the junction of L GE and trailer in about 75% of the 
population. To confirm this using another method, rHRSVB05dTom(5) genome 
ends were ligated (section 2.3.17). The ligated genome ends were reverse 
transcribed using priHRSV-B05-14873+ and from the cDNA, an amplicon was 
generated using priHRSV-B05-285- and priHRSV-B05-14966+ (Appendix 1). 
Sequence of the viral genome termini were verified by sanger dideoxy sequencing 
using priB05-204- and priB05-15063+. Sequences were aligned with 
rHRSVB05dTom(5) computer clone using DNASTAR SeqMan Pro software and it 
confirmed the presence of additional A in L GE (Figure 3.12C). This virus stock 
was used for some preliminary experiments in this thesis. 
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3.6 Multi-step growth analysis of rHRSVB05 expressing fluorescent protein 
rHRSVB05dTom(5) and rHRSVB05EGFP(5) growth kinetics were compared 
to determine if the insertion of dTom239 had an effect on virus growth. Growth 
kinetics was examined by multi-step growth analysis (section 2.2.8). HEp-2 cells 
were infected with rHRSVB05EGFP(5) or rHRSVB05dTom(5) at an MOI of 0.2. 
Supernatants from triplicate wells were collected at various time points (18 h.p.i. 
to 96 h.p.i.), an equal volume of 50% (w/v) sucrose was added to stabilize the virus 
during storage. Viral stocks were frozen at -80°C. Supernatants were thawed and 
the titer of virus was determined by TCID50 assay in Vero cells (Figure 3.13). Both 
viruses had titers of approximately 103 TCID50/ml at 24 h.p.i. The peak of infection 
was reached around 72 h.p.i. with titers of approximately 106 TCID50/ml. These 
data show that rHRSVB05dTom(5) grew comparably to rHRSVB05EGFP(5). 
Published data (Lemon et al., 2015) show that rHRSVB05 and rHRSVB05EGFP(5) 
have comparable replication kinetics.  
 
3.7 Human IVIG and human serum neutralization of rHRSVB05EGFP(5)  
 Human IVIG and human serum from plasma were used to develop a 
microneutralization assay for rHRSV. Three hundred p.f.u. of rHRSVB05EGFP(5) 
were incubated with or without varying concentrations of human IVIG (1:64000 to 
1:2000) or human serum (1:16000 to 1:500) for 1 hour at 37ºC in triplicate. 
Virus/antibody mixture was added to HEp-2 cells for 1.5 hours and growth medium
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was added. Infections were observed at 1 d.p.i. by phase-contrast microscopy and 
UV microscopy and the foci of infection were counted by observing EGFP 
expression. The mean of triplicate data was plotted with standard error. There was 
almost 50 percent reduction in number of foci of infection when IVIG at 1:16000 
dilution as compared to untreated control (Figure 3.14A). For human serum, 
1:1000 dilution was needed to reach over 50 percent as compared to untreated 
control (Figure 3.14B). 
 
3.8 rHRSVA11EGFP(5) and rHRSVB05EGFP(5) infections in vitro 
 Cotton rats are the gold standard in vivo small animal model for HRSV 
upper respiratory tract infection and are more susceptible to HRSV infection than 
mice (Bem et al., 2011; Boukhvalova et al., 2009). rHRSVB05EGFP(5) has been 
used to infect cotton rats (Lemon et al., 2015). To confirm that rHRSVA11EGFP(5) 
can infect cotton rat cells and to prepare for upcoming in vivo studies, transformed 
cotton rat lung cells were infected with rHRSVA11EGFP(5). Control infections were 
carried out in HEp-2 cells because they are commonly used in HRSV research. 
Cells were also infected with rHRSVB05EGFP(5), since it is known to be able to 
infect cotton rats (Lemon et al., 2015). HEp-2 cells were infected at an MOI of 0.1 
in triplicate, infections were observed by UV microscopy daily, and 
photomicrographs were obtained (Figure 3.15AB). Cotton rat lung cells were 
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readily infected with rHRSVA11EGFP(5) or rHRSVB05EGFP(5) at an MOI of 0.1 in 
triplicate (Figures 3.15C and 3.15D). This demonstrates both viruses infect cotton 
rat lung cells and the observed CPE in cotton rat lung cells is indistinguishable 
from that observed in HEp-2 cells.
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CHAPTER 4: DUPLICATION IN HRSVB05 GLYCOPROTEIN GENE 
 
4.1 Generation of pCG-HRSVB05GΔ60b  
  HRSVB05 is a BA genotype virus and contains a 60 nt duplication in the G 
protein gene. An expression plasmid, pCG-HRSVB05GΔ60b was generated to 
study HRSVB05 G protein lacking the duplication in MLD2 and the role of duplication 
in the successful spread of HRSV BA genotype globally. pCG-HRSVB05G 
(Figure 4.1A) was digested with Bmg BI and Pst I (section 2.3.3) and the 4,849 bp 
DNA fragment was gel extracted (section 2.3.4) to generate a linear vector (section 
2.3.4). A 479 bp DNA fragment (Figure 4.1B), containing the HRSVB05 G protein 
gene sequence from 30 bp upstream of the Bmg BI site and 22 bp downstream of 
Pst I site and with deletion of the second 60 nt of the duplication was synthesized 
by GeneArt. Vector and insert were assembled by Gibson assembly, a method of 
ligating multiple DNA fragments containing 15 to 80 bp sequence overlaps in one 
reaction (section 2.3.6). E. coli DH5α competent cells were transformed with one 
tenth of the total volume of the Gibson assembly reaction and plated onto LB agar 
plate containing ampicillin (section 2.3.8).  Six colonies were amplified in liquid 
culture and plasmids were isolated by small scale plasmid preparation (section 
2.3.9). Plasmids were verified by Bmg BI and Pst I restriction digestion (section 
2.3.3) and all plasmids contained the insert. Two plasmids were  sequenced by 
Sanger dideoxy sequencing using primers pripCG+ and pripCG-b (Appendix 1) to 
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Bmg BI
5’ 3’CMV
pCG-HRSVB05G (5,336 bp)
Pst IBmg BI
G
● ○
●
HRSVB05GΔ60b insert (479 bp)
G
Pst I
A
B
C
5’ 3’CMV
pCG-HRSVB05GΔ60b (5,276 bp)
Pst I
G
●
Bmg BI
TERDTSTPQSTVLDTTTSKH|TERDTSTSQSIALDTTTSKH
● ○
5’ 3’
Figure 4.1: Schematic diagram of construction of pCG-HRSVB05GΔ60b.
(A) pCG-HRSVB05G was digested with Bmg BI and Pst I to generate 4849 bp
linear vector. The 40 amino acids encoded by the duplicated region is
indicated with a vertical line for the separation between the tandem duplication.
● indicates the 20 amino acids encoded by first 60 nucleotides and ○ indicates
those encoded by the second 60 nucleotides. The amino acid differences in
the first and second half of the duplication are marked in red. (B) The insert,
HRSVB05GΔ60b, was synthesized by GeneArt. (C) A schematic diagram of
pCG-HRSVB05GΔ60b and the two restriction sites used for cloning. The grey
pentagons at the 5’ end indicate the CMV promoters used to control the
expression of the plasmids.
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sequence over the cloning sites and the insert (section 2.2.11). Sequences were 
aligned with pCG-HRSVB05GΔ60b (Figure 4.1C) computer clone using DNASTAR 
SeqMan Pro software (section 2.3.1) and no spurious mutations were identified in 
G protein gene. The sequence across the restriction sites and near the deletion of 
duplication is presented in Figure 4.2. Sequence verified bacterial clone was 
amplified in a liquid culture containing ampicillin, which was used to isolate plasmid 
by large scale plasmid preparation (section 2.3.10).  
 
4.2 Generation of pHRSVB05EGFP(5)GΔ60b 
A full-length antigenomic plasmid, pHRSVB05EGFP(5)GΔ60b, was 
constructed to study the modified G protein in the context of rHRSV. This plasmid 
can be used to recover HRSVB05 virus lacking the 60 nt duplication in the HRSV G 
protein gene. pHRSVB05EGFP(5) (Figure 4.3A) was digested with Bmg BI and the 
16,464 bp DNA fragment was gel extracted (section 2.3.4) to generate a linear 
vector. A 438 bp DNA fragment containing the deletion in HRSV G protein gene 
was amplified from pCG-HRSVB05GΔ60b (Figure 4.3B) by PCR (section 2.3.5) 
using priHRSV-B05-5132+ and priHRSV-B05-5586- (Appendix 1) and gel purified 
to generate insert 1 (I1). The 2609 bp DNA fragment with 41 overlapping nt with I1 
and 41 overlapping nt with the second Bmg BI site of HRSVB05 genome was 
amplified by PCR (section 2.3.5) from pHRSVB05EGFP(5) using priHRSV-B05-
5588+ and priHRSV-B05-8154- (Appendix 1) and gel purified (section 2.3.4) to 
generate insert 2 (I2). The 41 nt overlap was necessary for ligation of vector, I1, 
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and I2 (Figure 4.3C) by Gibson assembly (section 2.3.7). One tenth of the reaction 
was transformed into E. coli DH5α competent cells and plated onto LB agar plate 
containing ampicillin. Two colonies were amplified in liquid culture containing 
ampicillin and plasmids were isolated by small scale plasmid preparations. 
Plasmids were verified by restriction digests. The sequence of one plasmid 
containing both inserts was verified by Sanger dideoxy sequencing using priHRSV-
B05-4524+, priHRSV-B05-5014+, and priHRSV-B05-5916- (Appendix 1). 
Sequences were aligned with pHRSVB05EGFP(5)GΔ60b (Figure 4.3D) computer 
clone using DNASTAR SeqMan Pro software and HRSV G protein gene was 
confirmed to contain no spurious mutations (data not shown). Sequence verified 
bacterial clone was amplified in a liquid culture containing ampicillin and plasmid 
was isolated by large scale plasmid preparation. The sequence of the G protein 
gene, F glycoprotein gene, and M2-1 gene by Sanger sequencing using 
priHRSV-B05-4524+, priHRSV-B05-5014+, priHRSV-B05-5736+, 
priHRSV-B05-5916-, priHRSV-B05-6096+, priHRSV-B05-6503+, 
priHRSV-B0-6919+, priHRSV-B05-7435+, and priHRSV-B05-7611- (Appendix 1). 
Sequences were aligned with pHRSVB05EGFP(5)GΔ60b computer clone using 
DNASTAR SeqMan Pro software and no spurious mutations were identified. The 
sequencing result across the two restriction sites (Figure 4.4A), the insert-insertion 
junctions is presented in Figure 4.4B), the deletion of 60 nt (Figure 4.5).
 78 
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4.3 Recovery of rHRSVB05EGFP(5)GΔ60b 
 rHRSVB05EGFP(5)GΔ60b was recovered using the standard rHRSV rescue 
method (section 2.2.2) by transfecting HEp-2 cells in five wells of a 6-well plate. All 
five wells of transfected HEp-2 cells from primary rescue contained EGFP 
expressing cells and the cells in these wells were trypsinized and transferred into 
T75 flasks containing HEp-2 cells (section 2.2.2) (Figure 4.6A). One flask of cells 
from the primary rescue was passaged three times (section 2.2.3) to produce a P3 
stock virus (Figure 4.6B). The titer of P3 stock was determined to be   
104.94 TCID50/ml in Vero cells (section 2.2.6) 
 
 RNA was isolated (section 2.3.12) from rHRSVB05EGFP(5)GΔ60b stock and 
reverse transcribed using gene specific primers (Table 2.1) to generate cDNA 
(section 2.3.12). From the viral cDNA, amplicons were generated to overlap across 
the 15 kb full-length genome, which was sequenced to check for any spurious 
mutations in the viral genome (section 2.3.14). Sequences were aligned with the 
computer clone for rHRSVB05EGFP(5)GΔ60b across most of the genome using 
DNASTAR SeqMan Pro (section 2.3.1). However, a 638 bp gap from GE sequence 
of EGFP ATU to M protein gene and the genome termini have not yet been 
sequenced. Minor peaks were identified in the electrochromatogram at nucleotides 
3234 to 3718 within the GS sequence of EGFP ATU. These minor peaks matched 
with one nucleotide shift in sequence which suggested an insertion of an A 
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nucleotide in the seven repeating A’s at the end of the P protein GE 
polyadenylation signal (Figure 4.6C) for approximately 25% of sequences.  
 
4.4 rHRSVB05EGFP(5)GΔ60b passage preliminary experiment in HEp-2 cells 
 A preliminary experiment was performed to study if the region containing 
the duplication in the G protein gene was prone to acquiring mutations during 
passage in vitro. HEp-2 cells were infected in triplicate with rHRSVB05EGFP(5) P3 
stock or rHRSVB05EGFP(5)GΔ60b P3 stock at an MOI of 0.02. This infection was 
considered passage four (P4). Growth medium was replaced at 1 d.p.i. This 
process was repeated daily and when over 80% of cells were infected, as 
determined by EGFP expression, phase-contrast and UV photomicrographs were 
obtained (Figure 4.7). Cells were pelleted by centrifugation and the supernatant 
was used to infect HEp-2 cells in triplicate to set up passage five (P5) infection. 
Supernatant and cells were collected and stored at -80ºC for RNA isolation and 
subsequent sequencing of rHRSV. This process of imaging, passaging, and 
collecting was repeated nineteen times (Figure 4.7).  
 
Partial sequences of the virus at passage fourteen (P14) and passage 24 
(P24) were obtained to determine if there was a region in G protein gene that was 
more prone to occurrence of mutations. RNA was isolated from supernatants 
collected at P14 and P24 (section 2.3.12). RNA was used to determine the 
changes that arose in HRSVB05 G protein gene (section 2.3.14). Sequences were 
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aligned with computer clone of rHRSVB05EGFP(5) or rHRSVB05EGFP(5)GΔ60b, 
accordingly, using DNASTAR SeqMan Pro software. Although there were no 
complete changes in any nucleotide, heterogeneous sequence, as demonstrated 
by double peaks in electrochromatograms were seen. Data show mutations arise 
in various regions of the HRSV G protein gene during passage in HEp-2 cells and 
in this experiment no mutations were found in MLD2 where the duplication is 
located (Table 4.1). 
 
4.5 Generation of pHRSVB05EGFP(5)Gmycb and pCG-HRSVB05Gmycb 
 pHRSVB05EGFP(5)Gmycb was constructed to recover  
rHRSVB05EGFP(5)Gmycb, which will be used to examine changes at the site 
where the duplication occurs in HRSV G protein gene. pHRSVB05EGFP(5) (Figure 
4.8A) was digested with Bmg BI and 16,464 bp DNA fragment was gel extracted 
(section 2.3.4) to generate a linear vector. pMK-HRSVB05Gmycb (Figure 4.8B), 
plasmid containing partial HRSVB05 G protein gene with a c-myc epitope tag 
(Kolodziej and Young, 1991) encoding nucleotide sequence substituted within the 
second 60 nt of the duplication and partial F glycoprotein gene, was synthesized 
by GeneArt. The DNA fragment containing the c-myc epitope tag sequence 
substitution was amplified from pMK-HRSVB05Gmycb by PCR (section 2.3.5) using 
priHRSV-B05-5132+ and priHRSV-B05-5586- (Appendix 1) to generate insert A 
(IA). The DNA fragment with 41 overlapping nucleotides with IA and 41 overlapping 
nucleotides with the second Bmg BI site of HRSVB05 genome was amplified by 
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Table 4.1: Summary tables of G protein gene sequence analysis of
rHRSVB05EGFP(5) and rHRSVB05EGFP(5)GΔ60b after serial passaging in
HEp-2 cells. Sequence data have been summarized for (A)
rHRSVB05EGFP(5) and (B) rHRSVB05EGFP(5)GΔ60b passage experiment in
HEp-2 cells. RNA was isolated from P14 and P24 and reverse transcribed
rHRSV cDNA was used to sequence over the G protein gene. Population
column shows approximate percentage of the population contained the
mutation from the electrochromatogram. For each nucleotide, corresponding
amino acid (aa) position is presented.
passage nucleotide aa population (%)
14 U6145A 177 25
24 A6072G 153 25
24 A6073G 153 50
24 A6074G 154 25
24 A6075G 154 25
24 A6083G 157 25
24 A6084G 157 25
24 A6085G 157 25
24 A6096G 161 25
24 A6105G 164 <25
24 A6106G 164 <25
24 A6114G 167 25
24 A6141G 176 25
24 A6147G 178 <25
24 A6148G 178 <25
24 A6192G 193 25
24 C6216A 201 50
passage nucleotide aa population (%)
14 A5658G 15 75
24 A5658G 15 >75
24 U6134C 174 25
A
B
rHRSVB05EGFP(5)
rHRSVB05EGFP(5)GΔ60b
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PCR (section 2.3.5) from pHRSVB05EGFP(5) using priHRSV-B05-5588+ and 
priHRSV-B05-8154- (Appendix 1) to generate insert 2 (IB). Vector, IA, and IB were 
ligated by Gibson assembly (Figure 4.8C). One tenth of the reaction was 
transformed into E. coli DH5α competent cells and plated onto LB agar plate 
containing ampicillin. Ten colonies were amplified in liquid culture containing 
ampicillin and plasmids were isolated by small scale plasmid preparations.  
 
Plasmids were examined by restriction digests and DNA gel electrophoresis 
confirmed that the ligation was successful for eight plasmids (data not shown). Two 
plasmids were sequenced by Sanger dideoxy sequencing using priHRSV-B05-
5014+ and priHRSV-B05-7734+ (Appendix 1) to check the sequence across the 
Bmg BI sites. Sequences were aligned with the computer clone for 
pHRSVB05Gmycb (Figure 4.8D) using DNASTAR SeqMan Pro software and no 
spurious mutations around the restriction sites were found (data not shown). A 
single sequence verified bacterial clone was amplified in liquid culture containing 
ampicillin and plasmid was isolated by large scale plasmid preparation. Sequences 
of the EGFP ATU, G protein gene (Figure 4.9), F glycoprotein gene, and the Bmg 
BI restriction sites used for cloning was verified by Sanger dideoxy sequencing 
using priEGFP-339+, priEGFP-591+, priHRSV-B05-2916+, priHRSV-B05-3153+, 
priHRSV-3767-, priHRSV-B05-4109-, priHRSV-B05-4524+, priHRSV-B05-5014+, 
priHRSV-B05-5555+, priHRSV-5599-, priHRSV-B05-6251+, priHRSV-6743+, and 
priHRSV-B05-7435+ (Appendix 1). Sequences were aligned with the computer 
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clone for pHRSVB05EGFP(5)Gmycb using DNASTAR SeqMan Pro software and 
no spurious mutations were identified in the ATU and the G protein gene. The 
aligned sequence data for the duplication in G protein gene is presented in Figure 
4.9. One point mutation (A8033C), which would result in E463D amino acid change 
in the F glycoprotein was identified (Figure 4.10). 
  
 pCG-HRSVB05Gmycb was constructed using Gmycb sequence from 
pHRSVB05EGFP(5)Gmycb. pCG-HRSVB05GΔ60b (Figure 4.11A) was digested 
with Mlu I and Pst I (section 2.3.3) and the 4387 bp DNA fragment was gel 
extracted to produce a linear vector (section 2.3.4). An amplicon containing 
HRSVB05 G protein gene from pHRSVB05EGFP(5)Gmycb  (Figure 4.11B) was 
generated by PCR (section 2.3.5) using priRSV-B05-GORF+MluI and 
priRSV-B05-GORF-PstI (Appendix 1). These primers were used to add Mlu I 
restriction site upstream of the G protein gene sequences and Pst I restriction site 
downstream of the G protein gene sequences. The amplicon was purified and 
digested with Mlu I and Pst I (section 2.3.3). The 933 bp DNA fragment from the 
digestion was gel extracted to generate the insert (section 2.3.4). Vector and insert 
were ligated using T4 DNA ligase (section 2.3.7), one fourth of the ligation was 
transformed into E. coli DH5α competent cells, and transformations were plated 
onto LB agar plates containing ampicillin (section 2.3.8). Six colonies were 
amplified in liquid culture containing ampicillin and plasmids were isolated by small 
scale plasmid preparation (section 2.3.9). All plasmids were contained the insert
 90 
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when verified by restriction digest. A single bacterial clone was used for a large 
scale liquid culture containing ampicillin and plasmid was isolated by large scale 
plasmid preparation (section 2.3.10). Sequences of the plasmid at the restriction 
sites were verified by Sanger dideoxy sequencing (section 2.3.11) using pri-pCG+ 
and pri-pCG-b (Appendix 1). Sequences were aligned with the computer clone for 
pCG-HRSVB05Gmycb (Figure 4.11C) using DNASTAR SeqMan Pro (section 2.3.1) 
and no spurious mutations were identified at the cloning sites (Figure 4.12).  
 
4.6 Recovery of rHRSVB05EGFP(5)Gmycb  
rHRSVB05EGFP(5)Gmycb was recovered using pHRSVB05EGFP(5)Gmycb, 
which contained a point mutation in the F glycoprotein gene (section 2.2.2) (Figure 
4.9). Five days after transfection of the antigenomic plasmid and the HRSVB05 
expression plasmids (Figure 4.13A), six syncytia containing over thirty infected 
cells as determined by EGFP expression were picked and passaged onto HEp-2 
cells (section 2.2.3). This virus was passaged twice to generate a 
rHRSVB05EGFP(5)Gmycb P3 stock (Figure 4.13B). The titer determined to be 
105.81 TCID50/ml by TCID50 assay in Vero cells. 
 
Following rHRSV rescue, passage, and sequencing, many spurious 
mutations and heterogeneity were seen in the ATU, G protein gene, and F 
glycoprotein gene. Therefore, those regions of rHRSVB05EGFP(5)Gmycb P3 were 
sequenced first before sequencing the full-length genome. RNA was extracted
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from rHRSVB05EGFP(5)Gmycb P3 (section 2.3.12) and cDNA containing 
rHRSVB05 ATU, G protein gene, F glycoprotein gene were reverse transcribed 
using priHRSV-B05-2554+ (section 2.3.14) (Appendix 1). Three overlapping 
amplicons were generated (section 2.3.14) and they were sequenced by Sanger 
dideoxy sequencing (section 2.3.11) Sequences were aligned with the computer 
clone of rHRSVB05EGFP(5)Gmycb using DNASTAR SeqMan Pro software 
(section 2.3.1). No spurious mutations were identified from the ATU and G protein 
gene sequences. As expected, the mutation (A8033C) was present in the virus 
stock (Figure 4.13C).  
 
4.7 Characterization of rHRSVB05EGFP(5)Gmycb 
 Immunoblot analysis was performed to examine HRSVB05 Gmycb protein 
expression in rHRSVB05EGFP(5)Gmycb P3 infected HEp-2 cells in MLD2. 
Uninfected HEp-2 cells were used as a control. To generate positive control 
sample for anti-myc antibody, HEp-2 cells were transfected with pCG-Venus-cmyc, 
expressing a Venus/c-myc fusion protein. Venus is a 26.4 kDa yellow fluorescent 
protein derivative. HEp-2 cells were either transfected with pCG-HRSVB05Gmycb 
or infected with rHRSVB05EGFP(5)Gmycb at an MOI of 0.1. Lysates were prepared 
and samples were used for immunoblot analysis (section 2.2.10). The c-myc 
epitope tag was detected using a mouse anti-c-myc antibody and human β-actin 
was detected by mouse anti-β-actin antibody. Primary antibodies were detected 
using an anti-mouse IRDye 800CW secondary antibody. An image of the exposed 
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blot was obtained using an Odyssey CLx Imaging System (Figure 4.14). Specific 
binding of c-myc epitope tag by the anti-myc antibody was confirmed by 
Venus/c-myc fusion protein. There was a signal at approximately 30 kDa in cell 
lysates prepared from the pCG-Venus-cmyc transfected sample which 
corresponded to Venus/c-myc fusion protein. A protein was detected at 
approximately 90 kDa corresponding to HRSVB05 Gmycb protein in 
rHRSVB05EGFP(5)Gmycb infected lysates. HRSVB05 Gmycb protein was not 
detected in the lysates obtained from HEp-2 cells transfected with 
pCG-HRSVB05Gmycb. However, loading control β-actin was detected in all 
samples.  
 
Indirect immunofluorescence was used to examine HRSVB05 Gmycb 
localization in rHRSVB05EGFP(5)Gmyc infected cells. HEp-2 cells, grown on glass 
coverslips in a 6 well plate, were infected with rHRSVB05EGFP(5)Gmycb at an MOI 
of 0.1. Growth medium was changed at 1 d.p.i., cells were rinsed with DPBS, fixed 
with 4% (w/v) paraformaldehyde, and permeabilized with 0.5% (v/v) Triton-X100. 
Cells were treated with non-specific binding blocking reagents and HRSVB05 
Gmycb proteins were detected using mouse anti-myc epitope tag primary antibody 
and anti-mouse AlexaFluor 647 secondary antibody (section 2.2.11). Coverslips 
were mounted onto glass microscope slides using VECTASHIELD HardSet DAPI 
mounting solution. Cells were observed by UV microscopy and photomicrographs 
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were obtained using CLSM (Figure 4.15). Photomicrograph showed that 
rHRSVB05EGFP(5)Gmycb infected cells express EGFP in the cytoplasm and 
Gmycb proteins seem to be localized to the area surrounding the cytoplasm. 
Further investigation using a membrane stain will be necessary to confirm 
membrane expression of Gmycb proteins.   
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CHAPTER 5: SUB-CELLULAR LOCALIZATION OF HRSV POLYMERASE 
 
5.1 Generation of an expression plasmid for modified HRSV L protein 
pCG-HRSVB05LVenus, a plasmid expressing LVenus, was generated to study 
the effects of insertion of a fluorescent protein ORF into the VR between CRV and 
CRVI of the L gene of HRSV. The plasmid was constructed using pCG-HRSVB05L 
and pHRSVB05LVenus (Dr. Ken Lemon, QUB and Dr. Linda Rennick, BU). 
pCG-HRSVB05L (Figure 5.1A) was digested with Cla I (section 2.3.3), the 7,733 bp 
DNA fragment was gel extracted (section 2.3.4), and dephosphorylated using 
Antarctic phosphatase to generate a linear vector (section 2.3.7). pHRSVB05LVenus 
(Figure 5.1B) was digested with Cla I (section 2.3.3) and the 3,954 bp DNA 
fragment was gel extracted to generate the insert (section 2.3.4). Vector and insert 
were ligated using T4 DNA ligase (section 2.3.7) and one fourth of the ligation was 
used to transform E. coli DH5α competent cells. Transformed cells were plated 
onto LB agar plates containing ampicillin. Eight colonies were amplified in liquid 
culture containing ampicillin and plasmids were isolated by small scale plasmid 
preparation (section 2.3.9). Plasmids were verified by restriction digestion (section 
2.3.3), and three plasmids contained the insert (data not shown). Two of the 
plasmids were sequenced across the Cla I restriction sites by Sanger dideoxy 
sequencing (section 2.3.11) using pri-pCG-b, and priRSV-B-11038+ (Appendix 1). 
Sequences were aligned to the computer clone of pCG-HRSVB05LVenus (Figure 
5.1C) using DNASTAR SeqMan Pro software (section 2.3.1) and no spurious  
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mutations were found across the Cla I sites (Figure 5.2). A single clone was 
amplified in large liquid culture containing ampicillin and plasmids was isolated by 
large scale plasmid preparation (section 2.3.10).  
 
5.2 Modified HRSV L protein retains polymerase activity in mini-genome assay 
A mini-genome replication-transcription assay was performed to compare 
the RdRp activity of HRSVB05 L protein and HRSVB05 LVenus protein. RdRp activity 
of unmodified and modified HRSVB05 L proteins are similar in minigenome 
replication-transcription assay independent of the amount of L protein expression 
plasmid added (Figure 5.3). Data provided by Dr. Linda Rennick (BU). 
 
5.3 Characterization of rHRSVB05LVenus recombinant virus 
rHRSVB05LVenus was recovered from a full-length cDNA clone by Dr. Linda 
Rennick (BU). The growth kinetics of this virus was compared with 
rHRSVB05EGFP(5) by multi-step growth analysis. HEp-2 cells were infected with 
rHRSVB05EGFP(5) or rHRSVB05LVenus viruses at an MOI of 0.2. Supernatants from 
triplicate wells were collected, mixed with 50% (w/v) sucrose solution, and frozen 
at -80°C from 18 h.p.i. to 96 h.p.i., The virus titer in the supernatant at each time 
point was measured by TCID50 assay in Vero cells. The two viruses had similar 
growth kinetics with titer of less than 103 TCID50/ml at 18 h.p.i. and reaching peak 
titer at 72 h.p.i. with titer of about 106 TCID50/ml (Figure 5.4). This suggests
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modification of HRSV L protein by insertion of Venus protein in its VR did not affect 
virus replication in vitro in HEp-2 cells.  
 
HEp-2 cells, grown in glass-bottom dishes, were infected with 
rHRSVB05LVenus at an MOI of 0.02 to examine the expression and localization of 
LVenus protein (section 2.2.12). Infected cells were observed by UV microscopy  
17 h.p.i. Cellular membranes were detected with wheat germ agglutinin conjugated 
to AlexaFluor 594 and nuclei were detected with NucBlue Live ReadyProbes. Cells 
were supplemented with VectaCell Trolox Antifade Reagent in Leibovitz L-15 
medium with 20% (v/v) FBS and 100 U/ml of penicillin-streptomycin (section 
2.2.12). Leibovitz L-15 medium supports cell maintenance in the absence of 5% 
(v/v) CO2 and penicillin-streptomycin was used to prevent contamination. Living 
cells were imaged by CLSM with Leica TCS SP5 at 48 h.p.i. This demonstrated 
that the HRSV LVenus proteins were expressed and localized in inclusion bodies 
of various sizes, which are marked with white arrows (Figure 5.5). 
 
5.4 Modified HRSV L protein is equally sensitive to ribavirin 
Presence of Venus in the L protein of HRSVB05 had no effect on function and virus 
infectivity was equivalent to that of parental virus, rHRSVB05, in vitro. Ribavirin is a 
guanosine analog, which is the only FDA approved antiviral for HRSV. It was used 
to examine if HRSVB05 LVenus protein and rHRSVB05LVenus could be used to study  
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the effects of antiviral compounds on RdRp function and intracellular localization 
of the polymerase. 
 
A mini-genome replication-transcription assay was carried out in the 
absence or presence of varying amounts of ribavirin to compare its inhibitory effect 
on modified and unmodified HRSVB05 L protein (Dr. Linda Rennick, BU). A mini-
genome replication-transcription assay was performed in the presence or absence 
of various concentrations of ribavirin (1 µM, 5 µM, 10 µM, and 40 µM). RdRp 
activity of unmodified and modified HRSVB05 L protein were similar in each ribavirin 
treatment, with samples with luminescence of over 106 RLU when untreated and 
luminescence of under 104 RLU with 40 µM ribavirin treatment (Figure 5.6). This 
demonstrates that the HRSVB05 L protein activity in the presence of ribavirin was 
not affected by the presence of Venus in HRSVB05 L protein in vitro mini-genome 
replication-transcription assay. 
 
 The effects of ribavirin on the replication and transcription in the context of 
a virus infection was examined. HEp-2 cells, plated in 96-well plates, were infected 
with rHRSVB05EGFP(5) or rHRSVB05LVenus at an MOI of 0.2. Infected cells were 
treated with 0.1 µM, 1 µM, 5 µM, 7.5 µM, 15 µM, 30 µM, or 40 µM of ribavirin or 
left untreated. Phase-contrast and UV photomicrographs were obtained at 46 h.p.i. 
A decrease in fluorescence as the concentration of ribavirin increased was 
observed (Figure 5.7). In rHRSVB05LVenus infected cells, Venus expression was 
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localized to inclusion bodies. In rHRSVB05EGFP(5) infected cells, EGFP 
expression was diffuse throughout the cytoplasm. Supernatants from infected cells 
were collected and the titers were measured by TCID50 assay in Vero cells (section 
2.2.6). These were similar for the two viruses indicating that they were equally 
sensitive to ribavirin (Figure 5.8). Untreated samples contained 105 to 105.4 
TCID50/ml of virus and 40 µM ribavirin treatment decreased the titer to around 104 
to 103.3 TCID50/ml for both viruses. Cells were collected and lysed with Laemmli 
buffer and used for immunoblot analysis (section 2.2.10). HRSVB05 proteins were 
detected using goat polyclonal anti-HRSV primary antibody and anti-goat IRDye 
680RD secondary antibody. Images of immunoblot was obtained using LI-COR 
Oddyssey CLx imaging system and the N protein expression was quantified using 
LI-COR Image Studio software. Expression of N protein relative to untreated 
rHRSVB05EGFP(5) infection and untreated rHRSVB05LVenus infection was plotted 
for each ribavirin concentration. The N protein expression decreased equivalently 
for both viruses in the presence of increasing concentration of ribavirin (Figure 5.9).  
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CHAPTER 6: DISCUSSION 
 
6.1 Generation of rHRSV to study A and B antigenic subtypes  
Molecular characterization of HRSV antigenic subtypes A and B suggests 
a role of immune pressure in the prevalence of one subtype over another in a 
geographical region during a HRSV season (Melero and Moore, 2013). Short-lived 
subtype specific immunity has been described as the cause for this phenomenon 
from sequence analysis of circulating HRSV strains in various geographical 
regions (Agoti et al., 2015; Bose et al., 2015; Botosso et al., 2009; Tan et al., 2012). 
Understanding the basic differences in fitness of the two HRSV subgroups, 
comparing the pathology caused by each subgroup, and investigating the interplay 
between host immunity to strains of each subgroup is crucial in understanding the 
HRSV circulation patterns and development of vaccines (Coggins et al., 1998; 
Papadopoulos et al., 2004; Peret et al., 2000; Sullender, 2000). 
 
Chapter 3 of this thesis describes generation of multiple rHRSVs, to be used 
in functional assays in vitro and in vivo to compare the antigenic subtypes of HRSV 
and the host immunity to strains of each subgroup. HRSVA11, HRSV isolated in 
2011, was chosen as the representative strain for HRSV antigenic subtype A. 
pCG-HRSVA11L was generated to recover rHRSVA11 using HRSVA11 helper 
plasmids (section 3.1). pHRSVA11EGFP(5) was constructed (section 3.2) and used 
to recover rHRSVA11EGFP(5) (section 3.3). Identification of infected cells were 
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easier in rHRSVA11EGFP(5) infection in vitro (Figure 3.7) as compared to rHRSVA11 
infection (Figure 3.6) due to the expression of EGFP. This will be valuable in 
visualizing infected cells and identifying rHRSVA11EGFP(5) infection in co-infection 
models. pHRSVB05dTom(5) was constructed (section 3.4) to be used in recovery 
of rHRSVB05dTom(5) (section 3.5). This HRSV B subtype virus demonstrated 
similar growth kinetics as a rHRSVB05EGFP(5) (Lemon et al., 2015) (section 3.6). 
When the RNA genome ends of the three rHRSVs generated, rHRSVA11, 
rHRSVA11EGFP(5), rHRSVB05dTom(5), were analyzed by RACE (section 2.3.16), 
a heterogeneity at nucleotide 1 was observed for all (figures 3.8 and 3.12). Further 
analysis is necessary to determine whether this heterogeneity is due to a 
population of viruses which contain a uracil at the first nucleotide. Alternatively, this 
could be due to a population of viruses in which the first nucleotide was deleted 
and thymine appears in the electrochromatogram as an artifact due to the RACE 
protocol involving polyA tail step. Few other single nucleotide heterogeneity was 
observed for each of the rHRSV generated, but they were not identical between 
different rHRSVs (Figure 3.8, Figure 3.12).  
 
Using the two viruses generated in this chapter, an in vivo study in cotton 
rats was planned. To confirm that rHRSVA11EGFP(5) is able to infect cotton rat 
cells, cotton rat lung cells were infected (section 3.8). Similar to HEp-2 cell 
infection, infected cotton rat lung cells showed cell-to-cell fusion (Figure 3.15). 
HRSV microneutralization assay was optimized using human IVIG and human 
 116 
serum (section 3.7) to develop a method to determine the presence of neutralizing 
antibodies in immunized cotton rats. A cotton rat co-infection study (Dr. Linda 
Rennick, BU) using rHRSVA11EGFP(5) and rHRSVB05dTom(5) confirmed that they 
can be visualized within the tissues of the infected cotton rats by UV microscopy 
(figure 6.1). This experiment confirms that the tools developed in this chapter can 
be used to study the differences between HRSV of subtype A and B not only in 
vitro, but also in vivo. 
 
6.2 Generation of rHRSV to study the 60 nucleotide duplication in G protein gene  
BA genotype of HRSV, containing 60 nt duplication that was first described 
in Buenos Aires in 1998, is now found circulating globally as a predominant HRSV 
B genotype (Trento et al., 2003, 2010). It has been hypothesized that this 
duplication confers an advantage to the virus, but the role of the duplication has 
not been investigated until recently (Hotard et al., 2015). A study published in 2015 
characterized few functional differences of viruses with and without the 60 nt 
duplication (Hotard et al., 2015). A chimeric rHRSV containing the genome of A 
subgroup with a consensus G protein gene sequence from BA genotype viruses 
was used and a mutant of this rHRSV without duplication in G protein gene was 
generated. Data suggested that with the duplication, the virus binds to cells better 
in vitro, but there was no viral load difference in infection in mice with virus with 
and without duplication. We hypothesized that in addition to improved attachment, 
the duplication may also play a role in HRSV evasion of host’s adaptive immune 
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system. To limit the possible confounding factors resulting from using chimeric 
viruses, we used various rHRSVs generated from sequences of clinical isolates. 
 
In Chapter 4, multiple rHRSV were generated for investigating the role of 
duplication within MLD2 in success of BA genotypes. rHRSVB05EGFP(5) has been 
previously generated using a BA isolate from 2005 and it has been characterized 
(Lemon et al., 2015). Using pHRSVB05EGFP(5), pCG-HRSVB05GΔ60b and  
pHRSVB05EGFP(5)GΔ60b were constructed (section 4.1 and 4.2). 
rHRSVB05EGFP(5)GΔ60b was recovered using pHRSVB05EGFP(5)GΔ60b in 
which the 60 nucleotides in the duplication has been deleted (section 4.3). Having 
rHRSVB05EGFP(5) and rHRSVB05EGFP(5)GΔ60b allowed study of two viruses in 
which the only differences are in the presence duplication in the G protein gene. A 
preliminary serial passaging experiment was developed with rHRSVB05EGFP(5) 
and pHRSVB05EGFP(5)GΔ60b in the absence of immune pressure (section 4.3) to 
prepare for future studies looking at the changes that accrue in the HRSV G protein 
gene in the presence of immune pressure. HEp-2 cells were infected with either 
virus and the supernatant at each infection was passaged for 20 passages. The 
sequence analysis of viruses collected at two different passages suggested that 
even in the absence of immune pressure there are many random mutations that 
arise throughout the G protein genes and that most are accumulated in MLD1 and 
CD (table 4.1). Further studies are needed to determine if the differences in the 
number of mutations that arise in the passaging of rHRSVB05EGFP(5) and 
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pHRSVB05EGFP(5)GΔ60b are significant and if MLD2 accumulates mutations as 
readily as MLD1 and CD. rHRSVB05EGFP(5)Gmycb was recovered (section 4.5) 
using pHRSVB05Gmycb (section 4.4) to study the changes at the site of duplication 
in HRSV G protein and to provide a method of detection of HRSVB05 G protein. 
Gmycb expression in rHRSVB05EGFP(5)Gmycb infection was confirmed by 
immunoblot assay and indirect immunofluorescence (section 4.6).  
 
The recombinant viruses generated in this chapter not only provides tools 
to study the duplication in G protein gene and the mutation that occur in the 
duplicated region, but also basic HRSV G protein biology. The localization of G 
protein and expression level in various conditions can be studied using 
rHRSVB05EGFP(5)Gmycb, because Gmycb can be detected by c-myc antibodies 
that have been well characterized. Also, the serial passaging assay that was 
developed in chapter 4 can be modified by addition of immune pressure in the form 
of human IVIG, which has been shown to neutralize rHRSVB05EGFP(5) 
(section 3.7). This experiment will investigate the number of mutations that 
accumulate in the HRSV G protein gene in the presence and absence of 
duplication, the location of mutations that arise, and the advantage conferred by 
the 60 nt duplication in the presence of immune pressure.  
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6.3 Generation of rHRSV to study L protein  
 HRSV L protein has been difficult to study due to its large size, problems 
with purifying the protein, and lack of good antibodies against the protein for 
analyzing expression and localization (Fearns and Plemper, 2017). One way to 
overcome some of these problems would be to generate an L-reporter fusion 
protein. This method of inserting reporter protein sequence into L protein sequence 
of other NNS virus has provided us with insights into localization and tolerance of 
the L protein to modification (Brown et al., 2005; Hoenen et al., 2012; Ruedas and 
Perrault, 2009). Many NNS viruses tolerate insertion of reporter protein sequence 
into VR between CR V and CR VI in L protein (Figure 1.2B). However, it also 
attenuates the virus (Brown et al., 2005; Duprex et al., 2002; Ruedas and Perrault, 
2009; Silin et al., 2007). Investigators have inserted EGFP and mCherry 
sequences into the HRSV L expression plasmid at the sequence corresponding to 
VR. The resulting protein showed that there was downmodulation of RdRp activity 
of modified L protein in minigenome replication transcription assay (Fix et al., 
2011). 
 
 In chapter 5, modified HRSV L protein fused with a yellow fluorescent 
protein derivative, LVenus, and rHRSVB05 which expresses LVenus protein is 
presented. pCG-HRSVB05LVenus (section 5.1), with the modification in the HRSV L 
gene, was generated. LVenus protein expressed by pCG-HRSVB05LVenus retained 
RdRp activity in minigenome assay (section 5.2) and rHRSVB05LVenus growth was 
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not affected by L protein modification as compared to the growth of 
rHRSVB05EGFP(5) (section 5.3). CLSM analysis of rHRSVB05LVenus infected cells 
show that LVenus can be visualized in infected cells (figure 5.5). In the future, with 
optimization of live-cell imaging protocol, formation of inclusion bodies containing 
HRSV RdRp in rHRSVB05LVenus infected cells could be observed and trafficking of 
LVenus could be studied in living cells. Even with a lack of good HRSV L protein 
antibody, analysis of colocalization of LVenus with other HRSV proteins and host 
proteins becomes possible using rHRSVB05LVenus as a tool. 
 
 rHRSVB05EGFP(5) and rHRSVB05LVenus are equally inhibited by ribavirin, 
a FDA approved treatment for HRSV infection. This is shown by the comparable 
virus titer and viral protein expression level in an infection in the presence of 
various concentrations of ribavirin (section 5.4). In the future, effects of novel 
HRSV inhibitors on HRSV L protein expression and localization could be studied 
using rHRSVB05LVenus. This is important as more emphasis is put on finding HRSV 
inhibitors targeting HRSV L protein due to its essential role in HRSV infection 
(Fearns and Deval, 2016). 
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APPENDIX 1: PRIMER SEQUENCES 
 
Primer name Sequence (5’ -  3’) 
priB05-15063+ ACCTTCCTAATGAACAGTAAC 
priB05-204- GCTAATGCATTAGTCAGAAG 
pridTom240+PacI 
TCACTGATTAATTAACTATCCGGATCCGGATCCC
TTG 
pridTom25+BssHII 
GCAAATGCGCGCGAGATGGTGAGCAAGGGCGA
GGAGGTC 
priEGFP-339+ GAAGTTCGAGGGCGACAC 
priEGFP-591+ CGACAACCACTACCTGAG 
priEGFP-685+ GGGATCACTCTCGGCATG 
priHRSV-A10-10076+ AGTTTCGGTTGCCTAAAAA 
priHRSV-A10-10150- TGTGTGACGGCATATAATTT 
priHRSV-A10-103+ GCAGCAACTCATTGAGTG 
priHRSV-A10-10401+ GTTCAAATATTAGCAGAG 
priHRSV-A10-10771- ATCCACTTTGCTCATCTACA 
priHRSV-A10-11023+ AAGAGTATGCAGGAATAG 
priHRSV-A10-11648+ CGTTACATTGATGAGAGATC 
priHRSV-A10-12273+ GTTGGTTCATCTACACAAG 
priHRSV-A10-12600+ ACTAGCCCTATTAATCGCATA 
priHRSV-A10-12910+ ATTTAATATTGGCGCATAAG 
priHRSV-A10-13291- AGTTTGAAGCTATGACATCCT 
priHRSV-A10-13537+ CTCATCTATTAACTAAAC 
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priHRSV-A10-14144+ ACCAATTGAGTTTTTAAG 
priHRSV-A10-14854+ CATTTATATATGGTAGAATC 
priHRSV-A10-15171- AAAGTGTCAAAAACTAATATCTCG 
priHRSV-A10-1569+ CCAGAATACAGGCATGACTC 
priHRSV-A10-15838+ CGGCTTTCCCCGTCAAGCTC 
priHRSV-A10-1946+ CATTATGTTAGGACACG 
priHRSV-A10-2558+ CCCAATAAATGAGACAGATGA 
priHRSV-A10-2576+ CAATTATCAAAGAAAGC 
priHRSV-A10-2617- AAGGATTATCACTTGGCGTA 
priHRSV-A10-278- AGGGCAAATATCACTACTTGT 
priHRSV-A10-2803+ ACTAGGAATGCTTCACACATTAG 
priHRSV-A10-2924- CTTTTGCCATCTTTTCAC 
priHRSV-A10-3203+ AGCCACCCAGAAAAAATC 
priHRSV-A10-3285- GCAGCTGTGTATGTGGAG 
priHRSV-A10-3845+ TCAGGATTACTGTTAGTC 
priHRSV-A10-42+ AAACTTGCGTAAACCAAAAA 
priHRSV-A10-4390+ ATAATCTCCATCATGATTG 
priHRSV-A10-4426+ GATTGCAATATTAAACAAACTC 
priHRSV-A10-5046+ TTCAACAATACCAAGTGCTG 
priHRSV-A10-5095- GGTTTGCTAGGTGGTATTTG 
priHRSV-A10-5305+ CAAAAAAACCAACCATCAAG 
priHRSV-A10-5786- CAACCAGTTCTTAGAGCACT 
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priHRSV-A10-6231+ TTAACCAGCAAAGTGTTAG 
priHRSV-A10-6707+ GGATCAGTATCCTTTTTC 
priHRSV-A10-7158+ AGAAAATTAATCAGAGTC 
priHRSV-A10-7577+ CCAAATTAACTTACTATTTGTGAAA 
priHRSV-A10-7607- ATTTCGAATTTGCAAGGAT 
priHRSV-A10-8168+ ACCATGCCAAAAATAATG 
priHRSV-A10-8281- CCGGTGGGTATATATAGTTA 
priHRSV-A10-8617+ ATGGTCCTTATCTCAAAAATG 
priHRSV-A10-8639- GTGTTCTATTAATGGATTTTG 
priHRSV-A10-9102+ CATTGGTTTAACTTATAC 
priHRSV-A10-913+ GCACTTTCCCTATGCCAATA 
priHRSV-A10-9781+ CAATGGTAGATGAAAGAC 
priHRSV-A11-14918+ GAATTGTTAAACAGCTTGAC 
priHRSV-A10-42+ AAACTTGCGTAAACCAAAAA 
priHRSV-B05-10127+ TATCAGGATTGCGGTTCTAT 
priHRSV-B05-10145- TCATTTCAAGATCCACTTTTT 
priHRSV-B05-10309+ AGCGACAGATCAAGAAGAGTACT 
priHRSV-B05-10581- TGACTTGTTGCTTATTCCTGCT 
priHRSV-B05-10747+ ACTGCATGGGGTACAATCTCT 
priHRSV-B05-11757+ GGATCCACAGGCTTTAGGGT 
priHRSV-B05-12230+ AGTAGGAGTAACATCGCCAAGT 
priHRSV-B05-12609+ CTGCCTCAATACCAGCTTAT 
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priHRSV-B05-1262+ ACACTCCCAATTATGATGTGCA 
priHRSV-B05-12687- TGTCGATATCTTCATCTCCA 
priHRSV-B05-12815+ TCTCATACCGAAGCTGAATGAG 
priHRSV-B05-13104- ACCCCTCTCCCCAATCTTTT 
priHRSV-B05-13598+ CTCTTTTACATTAGTTATAAC 
priHRSV-B05-14176+ GTAGAACTTCATCCTGACATAAG 
priHRSV-B05-14604+ CCTTACAATAGGCCCTGCAA 
priHRSV-B05-15214- AATGCACATGTGTGATTGTT 
priHRSV-B05-169+ TTATTTGACAATGACGAAGTAGCA 
priHRSV-B05-1745+ CGCTACAAGGGCCTAATACC 
priHRSV-B05-2225+ GAGCAACTCAAAGAAAATGGAGT 
priHRSV-B05-2554+ ATCAATCCAACAAGTGAAGC 
priHRSV-B05-2579- TAGGGGTTTTCTTGGGTAGT 
priHRSV-B05-2916+ GAGCAGAAGCATTAATGACCAATG 
priHRSV-B05-3084- GTTGTTGATTGCTGAGTGAG 
priHRSV-B05-33+ TGCGTACTACAAACTTGCACA 
priHRSV-B05-3698+ CCACTCATGAGATCATTGCT 
priHRSV-B05-3767- GTTCAGGTCCTTGTTTTTGA 
priHRSV-B05-3936+ GCCACAGAGTCAATTTATAGTGG 
priHRSV-B05-4109- TGTGATGAAGTGTGTAGTGT 
priHRSV-B05-4524+ TCTCCCATTATGCTGTGTCAA 
priHRSV-B05-5014+ CAAACAACCCACAACCACAC 
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priHRSV-B05-5087+ CACCATACAACAGCACAAAC 
priHRSV-B05-5132+ CACAGAACAACAAGCCAAGCAC 
priHRSV-B05-5555+ TCTCTCTACTCAACCACCCC 
priHRSV-B05-5586- ATGTGGAGGGCTCGGATGCTG 
priHRSV-B05-5588+ CAACTCCACACAAACACCCAC 
priHRSV-B05-5599- AGGTGGAATTTGATGTGGAG 
priHRSV-B05-5650- GGTTCTCTGCTAAGATGTAGTTT 
priHRSV-B05-5736+ ACCATGGAGTTGCTGATCCA 
priHRSV-B05-5916- TCAGTTCCATTGCATTTGGT 
priHRSV-B05-6096+ TCTGGGCTTCTTGTTAGGTG 
priHRSV-B05-6251+ TGCTGTCTACAAACAAAGCTG 
priHRSV-B05-6503+ TAATGTCAAGCAATGTTCAG 
priHRSV-B05-6743+ ACAAGGACTGATAGAGGATGGT 
priHRSV-B05-6919+ GCTATAGTGTCATGCTATGG 
priHRSV-B05-739+ CACCAAAGAAATCATCACACACA 
priHRSV-B05-7435+ GAATCAATAATATTGCATTC 
priHRSV-B05-7574+ TCATGCTACCCACACAACTA 
priHRSV-B05-7609- TTTAGTGTTGATTGCGATATTT 
priHRSV-B05-7611- GCAGGGATTTCTTCGCGAC 
priHRSV-B05-7788+ TGCATTACTAGTGAGGCAAA 
priHRSV-B05-7870- AGAGCATATTCTTCTGTTCT 
priHRSV-B05-8154- TTGTGGATATCTAATGTGTTC 
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priHRSV-B05-8230+ ACCGTAAGTGATCAAAATGACCA 
priHRSV-B05-8734+ ACAAAGCCCACTACTAGAGCA 
priHRSV-B05-9476+ CTTAGGGTTGAGATGCGGATTC 
pripCG+ CAGCTCCTGGGCAACGTG 
pripCG-b TTATTAGCCAGAAGTCAG 
priRSV-A10-10401+ GTTCAAATATTAGCAGAG 
priRSV-A10-11023+ AAGAGTATGCAGGAATAG 
priRSV-A10-11648+ CGTTACATTGATGAGAGATC 
priRSV-A10-12273+ GTTGGTTCATCTACACAAG 
priRSV-A10-12910+ ATTTAATATTGGCGCATAAG 
priRSV-A10-13537+ CTCATCTATTAACTAAAC 
priRSV-A10-14144+ ACCAATTGAGTTTTTAAG 
priRSV-A10-2576+ CAATTATCAAAGAAAGC 
priRSV-A10-278- AGGGCAAATATCACTACTTGT 
priRSV-A10-4390+ ATAATCTCCATCATGATTG 
priRSV-A10-5305+ CAAAAAAACCAACCATCAAG 
priRSV-A10-5761+ ATTTTATCAATCAACATG 
priRSV-A10-6231+ TTAACCAGCAAAGTGTTAG 
priRSV-A10-8489+ CAAGCTATGGGACAAAATG 
priRSV-A10-9102+ CATTGGTTTAACTTATAC 
priRSV-A-14854+ CATTTATATATGGTAGAATC 
priRSV-A-2637+ CTATACAAAGAAACCATAG 
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priRSV-A-3528+ GTGTCCTTGGATGAAAGAAGC 
priRSV-A-9051- CCATGATGGAGGATGTTGC 
priRSV-B05-GORF+MluI ACGCGTGCCACCATGTCCAAAAACAAGAATC 
priRSV-B05-GORF-PstI TATATACTGCAGTTAGGTGGAATTTGATGTG 
priRSV-B-285R GTTATCAGGGCACACTTCAC 
priRSV-B-3267+ ACAAGATGGGGCAAATATGG 
priXFP-22+ ATGGTGAGCAAGGGCGAGGAG 
priXFP-698- CTTGTACAGCTCGTCCATG 
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APPENDIX 2: ANTIBODIES 
 
Antibody Source (product) Working dilution 
Anti-c-myc  GenScript (A00704-40) 1:1000 (IB); 1:500 (IF) 
Anti-goat IRDye 680RD LI-COR (925-68074) 1:10,000 (IB) 
Anti-mouse IRDye 
CW800 
LI-COR (925-32212) 1:10,000 (IB) 
Anti-respiratory 
syncytial virus  
Abcam (ab20745) 1:500 (IB) 
Human IVIG CSL Behring (Privigen)  
Human serum Atlanta Biologicals (S40190)  
Wheat germ agglutinin 
AlexaFluor 594 
Invitrogen (W11262) 1mg/ml (IF) 
Anti-human β-actin Abcam (ab8226) 1:2000 (IB) 
    
      IB: immunoblot         IF: immunofluorescence  
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